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DEFINING THE ROLE OF TUMOR SUPPRESSOR DEAR1 IN THE ACQUISITION OF
MAMMARY STEM/PROGENITOR CELL PROPERTIES
Uyen Quynh Nguyen Le, B.S.
Supervisory Professor: Ann Killary, Ph.D.
Breast cancer is the most commonly diagnosed cancer in women in America. Ductal
carcinoma in situ (DCIS), one of the earliest pre-invasive forms of invasive ductal carcinoma
(IDC), has a 30-50% risk of progressing to IDC. Understanding the mechanisms regulating
progression from DCIS to IDC would help identify biomarkers to stratify patients at higher risk of
progression or metastasis. Cumulative literature suggests the earliest phase of dissemination
from the primary tumor is driven by the epithelial-mesenchymal transition (EMT) program.
DEAR1 is a tumor suppressor gene which is mutated, undergoes loss of heterozygosity in breast
cancer, and is downregulated in DCIS lesions and IDC. DEAR1 regulates acinar morphogenesis
and cell polarity and is a negative regulator of TGF-β-driven EMT through inhibition of SMAD3.
Studies have now demonstrated that induction of EMT promotes acquisition of stem/progenitor
cell properties, further adding to the repertoire of cellular regulation by EMT mediators.
I demonstrate that loss of DEAR1 in human mammary epithelial cells (HMECs) and DCIS
cells results in a mammosphere phenotype independent of the canonical TGF-β pathway,
suggesting that DEAR1 regulates stem/progenitor cell properties. DEAR1-knockdown (KD)
HMEC mammospheres express high levels of stem/progenitor cell marker aldehyde
dehydrogenase (ALDH1) and display a basal-like phenotype through repression of CD24 and
EpCAM expression. There is significant upregulation of master EMT and stem cell regulators,
including SNAI2, in DEAR1-KD HMECs and I show that DEAR1 binds to and promotes
polyubiquitination of SNAI2. I reveal a novel DEAR1-SNAI2 axis that partially regulates
stem/progenitor cell properties in HMECs and demonstrate a significant association between
loss of DEAR1 in basal-like/triple-negative breast cancers (TNBC), early-age of onset, and risk
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of shorter time to metastasis in TNBC. Additionally, I identify a possible mechanism governing
DEAR1 regulation in mammary epithelial cells through miRNAs miR-10b and miR-196b.
Results herein demonstrate that DEAR1 promotes stem/progenitor cell properties
partially through TGF-β-mediated EMT and also through SNAI2 independently of TGF-β-SMAD3
signaling. I hope to use this understanding of DEAR1 and its regulation of cell polarity, EMT, and
stemness to stratify high risk patients who would benefit from more aggressive or targeted
therapy.
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CHAPTER 1: Background and significance

1

1.1

Ductal Carcinoma In Situ and Invasive Ductal Carcinoma
Breast carcinoma remains the most commonly diagnosed cancer in women in the United

States and is the third-leading cause of cancer-related deaths, led by colorectal and lung
carcinomas. It is estimated that there will be approximately 266,120 new cases and 40,920
deaths from breast cancer in 2018. The median age of diagnosis is 62 years of age and the
average 5-year survival rate is nearly 90%. The majority of patients are diagnosed when the
disease is at an early, localized stage in which the 5-year survival rate is quite favorable (nearly
99%); however, if diagnosed after the cancer has metastasized the 5-year survival rate
significantly drops to 27% [1]. This highlights the importance of diagnosing and rendering
appropriate treatment when the disease is at its earliest stage to reduce morbidity and mortality.
Breast cancer subtypes
Breast carcinomas have been traditionally categorized into subtypes based on
expression of hormone receptors for ER (estrogen), PR (progesterone), and growth factor
receptor HER2 using immunohistochemistry (IHC) staining of tumor tissues. This standard
method of classification has been further elucidated by Perou and colleagues through gene
expression profiling to correlate gene expression patterns with hormone receptor status
classification and clinical outcome, categorizing tumors into intrinsic subtypes that also
corresponds well with the IHC status [2-4]. Tumors that fall into the luminal A subtype
demonstrate high expression of ER and/or PR but lack HER2 overexpression. This tumor
subtype is typically low-grade, slow-growing, has the most favorable prognosis, and is the most
common subtype, accounting for 30-50% of all breast cancer cases. Luminal A tumors are
characterized by low expression of proliferation genes, low Ki67, and high expression of CK8/18
luminal cytokeratin, GATA3, and BCL2. [5, 6]. The luminal B subtype is also ER/PR positive, can
be either HER2 negative or positive, and has high Ki67 staining. One key difference between
luminal A and luminal B tumors is that luminal B tumors tend to exhibit higher expression of
proliferation-related genes such as v-MYB, GGH, LAPTMB4, NSEP1, and CCNE1 and lower
expression of ER-related genes [6, 7]. Activation of growth-promoting pathways, such as FGFR1
2

and PI3K, are also implicated in luminal B cancers [8]. HER2 positive tumors are generally ER/PR
negative and overexpress HER2, a tyrosine kinase receptor mapped to Chromosome 17q21.
HER2 positive tumors often have acquired TP53 mutations, are of higher grade, are highly
proliferative, and, in the absence of treatment, have a worse prognosis compared to luminal
subtypes [5, 6]. According to the SEER database, approximately 10% of all breast cancer cases
diagnosed in 2010 were of the HER2 subtype [9]. The aforementioned subtypes of breast cancer
express surface markers that can be utilized for targeted therapies (e.g. trastuzumab/Herceptin
against HER2 positive tumors). The triple negative breast cancer (TNBC) subtype is
characterized by lack of ER, PR, and HER2 expression, making this disease difficult to apply
targeted hormone therapies. TNBC patients have poor prognosis compared to luminal and HER2
positive subtypes. TNBCs are associated with BRCA1 mutations, younger age of diagnosis, high
grade tumors, higher risk of metastasis and recurrence, and high proliferative indices [10, 11].
TNBCs can be further categorized into subtypes based on differences in gene expression profiles
and biological pathways. One well-known subtypes of TNBC is the basal-like classification that
accounts for up to 70% of TNBCs and is characterized by high expression of myoepithelial/basal
markers (e.g. cytokeratin 5 & 14), TP53 mutations, RB inactivation, and expression of genes
involved in matrix remodeling [5, 6]. It is imperative that we acquire a deep understanding of the
biology of this disease in order to provide more effective treatment options.
Ductal carcinoma in situ
Various factors can contribute to the risk of breast cancer, including age, family history,
genetic alterations (e.g. TP53, HER2, BRCA1/2), and hormone replacement therapy [12]. The
two subtypes of breast carcinomas are lobular and ductal carcinomas, the latter constituting
approximately 80% of breast carcinomas worldwide [4]. The current linear model of breast cancer
progression begins with the evolution of normal mammary epithelial cells to flat epithelial atypia,
followed by atypical ductal hyperplasia (ADH) that can progress to ductal carcinoma in situ
(DCIS) and invasive ductal carcinoma (IDC). The development of mammography and its utility in
clinical screenings since the 1980s has led to an increase in the incidence rate of breast cancer
3

annually [13, 14]. Approximately 25% of newly diagnosed cases are DCIS, one of the earliest,
pre-invasive forms of IDC that is considered Stage 0 breast cancer [12, 14]. DCIS is defined as
a neoplastic proliferation of mammary epithelial cells that remains confined within the ductallobular system and the non-obligate precursor of IDC. Although DCIS does not inherently
progress to invasive ductal carcinoma, if left un-treated up to 60% of low-grade DCIS can
progress to invasive disease within 10 years [12, 13, 15]. The current standard treatment for
DCIS is surgery followed by radiation therapy. This treatment regimen reduces recurrence risk
to approximately 8%, in which about half of these recurrences are invasive and have up to a 20%
chance of metastasizing within 8 years [12]. It remains unknown how best to identify which cases
are at risk for progression to IDC and which cases will remain indolent, posing the issue of overor under-treatment of this disease.
There are known risk factors that contribute to recurrence, such as surgical margins,
nuclear grade, age of onset, and presence of comedonecrotic lesions [12]. However, the precise
mechanisms and pathways responsible for recurrence and progression are still poorly
understood. Several studies have demonstrated that while there are few dramatic genetic and/or
expression profile differences between synchronous DCIS and IDC [4, 14, 16, 17], there seem
to be significant differences between pure DCIS and DCIS with invasive components, as well as
between low-grade and high-grade DCIS, the latter of which has a higher risk of local recurrence,
metastasis after invasive recurrence, and poor disease-free survival [13, 18]. The fact that pure
DCIS and DCIS with invasive components harbor different genetic aberrations and that DCIS
associated with invasive components and matched IDC samples demonstrated a significantly
greater number of predicted driver mutations compared to pure DCIS, such as BRCA2, FGFR2,
EPHA1, DCLK3, and PTPRB, suggests that progression from DCIS to invasive carcinoma is
driven by the selection of cells that have accumulated an advantageous repertoire of genetic
alterations [14, 16, 17]. There is also strong evidence that genetic and/or epigenetic alterations
in stromal cells that comprise the extracellular matrix (ECM) can have a significant impact on
invasion, migration, and metastasis [4, 19-21].
4

Breast cancer cell of origin theories
It is well understood that DCIS/IDC is a heterogeneous disease, and the complexity of
the genetic and/or epigenetic changes that occur in cells that form tumors make it difficult to treat.
There are currently two popular hypotheses, not undeniably mutually exclusive, that demonstrate
the heterogeneous nature and cell origin of breast carcinogenesis (Figure 1.1). Both hypotheses
agree on the concept that tumors are formed from one transformed cell through acquisition of
mutations, but they pose different explanations regarding the target cell that undergoes
transformation, heterogeneity, and resistance. The first is termed the sporadic clonal evolution
model (Figure 1.1A), which postulates that all cells are targets of random mutagenesis. These
cells accumulate mutations over time, and advantageous mutations that provide cells with the
ability to proliferate and form a tumor are selected for. Heterogeneity, based on this theory,
comes from the multitude of various mutations individual cells undergo throughout their lifecycles.
Resistance to chemotherapeutic drugs is believed to occur through selection of specific clones
that have acquired the necessary mutations for survival [21, 22]. The second hypothesis is
termed the cancer stem cell model in which a normal mammary stem cell is transformed into a
mammary cancer stem cell that retains its ability to self-renew, creating more cancer stem cells,
as well as generates differentiated, cancerous progeny of various subtypes (Figure 1.1B). Based
on this second model, heterogeneity is generated through the differentiation of cancer stem
and/or progenitor cells into lineage-specific mammary cells and drug resistance is an inherent
property of cancer stem cells due to their quiescent nature [21, 23]. Though the two models of
breast carcinogenesis differ in respect to the origin of the tumor-initiating cell, they are not
necessarily mutually exclusive. It is possible that a non-stem cell is transformed and acquires
stem cell-like properties through accumulations of mutations. Conversely, it is possible that a
transformed stem cell acquires mutations over time and is selected for during clonal evolution.
The fact remains that heterogeneous tumors are difficult to treat due to the varying genetic
alterations of each cell in the bulk population. A clear understanding of precise pathways and
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Figure 1.1: Cancer cell of origin theory. The cancer cell origin theory postulates that tumors
arise from one single cell that has acquired mutations necessary for transformation. A) The clonal
evolution model proposes that any normal cell is a target of transforming mutations. Over time,
transformed cells acquire selective advantages due to accumulation of various mutations that
allow them to proliferate. B) The stem cell model hypothesizes that tumors are analogous to
organs with uncontrolled growth, therefore the cell of origin must be similar to stem cells are
capable of self-renewal and generating other cell types.

6

mechanisms that drive DCIS development, as well as progression to IDC, will help determine the
most effective forms of therapies for these patients.
1.2

Epithelial-Mesenchymal Transition (EMT) and its role in carcinogenesis
Epithelial cells, which constitute the lining of major organs and generate glandular

structures, have the unique ability to form sheets and tubes that are essential to organ function
and are characteristically immobile [24]. Maintenance of these structures depends highly on cellcell adhesion, accomplished through formation of cellular junctions and apical-basal polarity,
which is designated through localization of particular polarity protein complexes and is unique to
epithelial cells [25-27]. On the other hand, mesenchymal cells are highly mobile and are capable
of generating an extracellular matrix to support epithelial structures [24]. In certain
circumstances, such as during organ development or wound healing, epithelial cells shed their
epithelial phenotype and acquire mesenchymal characteristics. This process is called EMT that
begins with loss of cell polarity and adhesion followed by acquisition of migratory and invasive
potential.
Apical-basal polarity and cell adhesion
Maintenance of cell polarity is achieved through various protein complexes that dictate
apical and basal regions. These polarity protein complexes also associate with protein structures
that form junctions between cells to achieve cell-cell adhesion. The PAR complex, consisting of
PAR6, PAR3, and aPKC proteins, and Crumbs complex, consisting of CRB, PALS1, and PATJ
proteins, segregate to the apical portion of epithelial cells and are associated with tight junctions.
The Scribble complex, which is comprised of SCRIB, DLG, and LGL proteins, localize to the
basolateral portion and are associated with adherens junctions [25, 27]. Tight junctions and
adherens junctions are crucial mediators of cell-cell contact. While tight junctions function to
regulate transportation of ions between neighboring cells through association of occludins,
claudins, and ZO proteins, adherens junctions initiate and maintain cell-cell adhesion mediated
by E-cadherin and catenins [28]. Specific junctions called gap junctions and desmosomes are
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localized to the lateral portion of epithelial cells. Desmosomes are responsible for providing
strength between adjoining cells through protein complexes that consist of members of the
desmocollin and desmoglein family of proteins that link to plakophilins and plakoglobins of the
armadillo family. Armadillo proteins are connected to desmoplakin proteins that are directly
bound to intermediate filaments within the adjacent epithelial cell [27]. Epithelial cells are also
anchored to the basement membrane through hemidesmosomes that are connected to
cytokeratins within the cell and bound to transmembrane proteins called integrins that bind to the
ECM [27]. Together, these complexes regulate and maintain cell polarity and adhesion that is
characteristic of an epithelial phenotype.
Types of EMT
The discovery that epithelial cells can convert to a mesenchymal phenotype through a
process called EMT was primarily established through observations made in chicken embryos
by Elisabeth Hay in the early 1980s [29]. EMT is a highly regulated process that is crucial during
embryogenesis and development, and is activated throughout the adult lifespan during wound
healing and scar tissue formation. EMT is a mechanism by which immobile epithelial cells lose
their apical-basal polarity, detach from neighboring cells and the basement membrane through
disruption of the cellular adhesion complexes discussed above, acquire migratory potential, lose
epithelial markers such as cytokeratins and E-cadherin, and display a mesenchymal-like
phenotype including overexpression of vimentin and N-cadherin. Activation of the EMT process
has now been demonstrated as a major driver of invasion and metastasis in epithelial cancers
[24-27, 30].
The EMT process can be distinguished into three types based on the specific context in
which it occurs. Type I EMT, also known as developmental EMT, is strictly controlled and is first
witnessed during gastrulation, a process that results in the generation of the three germ layers
in a fertilized egg. Type I EMT is most notably controlled through Wnt signaling, which can be
modulated through Nodal and Vg1, members of the transforming growth factor beta (TGF-β)
superfamily of proteins [24, 30]. A type II EMT is associated with wound healing and fibrosis, a
8

phenomena characterized by a prolonged inflammatory response due to injury. It has been
observed that during fibrosis, cells can undergo what is termed as a “partial EMT” in which cells
express mesenchymal markers but still maintain a relatively epithelial phenotype. This partial
EMT has been demonstrated to be regulated by the release of TGF-β, platelet-derived growth
factor (PDGF), epidermal growth factor (EGF), and fibroblast growth factor 2 (FGF-2) by
macrophages and fibroblasts, which are recruited to sites of injury. Inflammatory cells can also
secrete metalloproteases, notably MMP-2, MMP-3, and MMP-9, to facilitate the release of
epithelial cells from the basement membrane [30]. Finally, type III EMTs occur in the context of
carcinogenesis where transformed, carcinoma cells acquire a mesenchymal phenotype and
become highly invasive. The ability to break from neighboring cells and the basement membrane
allows cancer cells to initiate the multistep metastatic process by which cells are required to
intravasate into the bloodstream, survive circulation, leave the bloodstream (extravasation),
generate micrometastases at a distant site, and finally colonize the secondary tumor [30, 31]. It
was observed that cells from secondary tumors resemble their primary tumors; the fact that they
have reverted back to an epithelial phenotype and no longer express mesenchymal markers
suggests that to form micrometastases after extravasation requires migratory mesenchymal cells
to convert back into epithelial cells through the reverse process termed mesenchymal-epithelial
transition (MET) [24-27, 30, 32]. Despite being classified based on biological function, the EMT
process in all three types share similar regulatory elements in terms of activation and signaling
pathways that mediate this physical phenomena.
Key steps for initiation of the EMT program
It is agreed upon that initiation of EMT consists of a set of crucial events that includes: 1)
loss of adhesion and cell polarity, 2) changes to the cytoskeleton that mediate an enhanced
motility phenotype, and 3) differential gene expression as cells shift from epithelial to
mesenchymal phenotype [24-27, 30].
Loss of cell-cell contacts can be achieved through transcriptional regulation, posttranscriptional regulation (e.g. ubiquitination and proteasomal degradation), or through inhibition
9

of maintenance pathways affecting components of adhesion junctions [25, 27]. For example, loss
of E-cadherin gene expression, through copy number alterations, mutations, or promoter
methylation, or phosphorylation of β-catenin, which binds directly to E-cadherin at adherens
junctions, through activation of Wnt signaling leads to destabilization and decreased cell
adhesion [27]. Loss of E-cadherin is observed frequently in breast carcinomas, is associated with
high grade tumors and invasive behavior, and confers poor prognosis [33, 34]. Loss of cell
adhesion also confers loss of cell polarity as polarity complexes also undergo dissolution [25].
Rearrangement of the cytoskeleton is required for cells to elongate, thereby acquiring a
spindle-shaped morphology that is characteristic of mesenchymal cells, and present directional
polarity. Cytoskeletal reorganization is regulated by RHO GTPases, which modulate actin
filaments, and RAC1 and CDC42, which are involved in lamellipodia and filopodia formation and
recruited to the leading edge of the migrating cell through PI3K signaling [25, 27].
EMT is initiated by extracellular signals and processed through activation of membrane
receptors that in turn lead to activation of intracellular signaling pathways that eventually cause
changes in gene expression to achieve the physical changes discussed above [27]. Changes in
gene expression to alter cellular adhesion include repression of junction proteins, such as
cytokeratins, cadherins, claudins, occludins, and integrins. Activation of the EMT program also
results in upregulation of mesenchymal markers, such as N-cadherin, NCAM, vimentin, and
fibronectin, as well as metalloproteases to facilitate ECM breakdown [25-27].
TGF-β is a potent inhibitor of cell proliferation and inducer of EMT
There are several known inducers of the EMT program, including growth factors EGF,
hepatocyte growth factor (HGF), insulin growth factor 1 (IGF-1), and FGF. The most well
characterized and studied is the TGF-β superfamily of proteins, which includes TGF-β1, TGFβ2, and several bone morphogenetic protein (BMP) cytokines [25]. De Larco and Todaro first
publicized the discovery of TGF-β in 1978 [35]. Shortly after, its role in inhibiting proliferation in
BSC-1 monkey kidney cells was established by Holley and colleagues [36]. In the 1980s, Moses
and colleagues demonstrated that TGF-β could inhibit proliferation of several cell types [37] and
10

Silberstein and Daniel were the first to show that TGF-β can inhibit mammary gland development
in mice and that this inhibition was reversible with removal of TGF-β ligand [38]. TGF-β has been
shown to induce expression of cell cycle inhibitors, namely p15INK14B, an inhibitor of CDK4 and
CDK6, and c-Myc [39-41]. Despite its obvious role in inhibiting cell proliferation in vivo and in
vitro, it was observed that TGF-β, most notably TGF-β1, is upregulated in multiple cancers [39,
42]. It became clear that TGF-β plays dual roles depending on cellular contexts [39, 43-45]. In a
study by Basolo et al, TGF-β inhibition affected proliferation of untransformed or spontaneously
immortalized mammary epithelial cells but not cell lines that were transformed by the SV40-largeT antigen, suggesting that inactivation of the tumor suppressors Rb and/or p53 can subvert the
anti-proliferative effect of TGF-β signaling [46]. Further studies provided evidence that TGF-β
signaling inhibits growth in the context of normal cells and at early stages of tumorigenesis, but
due to the accumulation of genetic alterations and genomic instability during carcinogenesis,
TGF-β signaling becomes tumor promoting at later stages of tumorigenesis and its role in
initiating EMT becomes an important mediator of metastasis [39].
TGF-β ligands bind to combinations of type I and type II TGF-β receptors, which are
transmembrane serine/threonine kinases [39]. Currently there are seven and five known type I
and type II receptors, respectively, and 29 ligands in mammals. Signaling is initiated when a
ligand binds and activates a type II receptor kinase of the heteromeric receptor complex, resulting
in phosphorylation and activation of a type I receptor. Different ligands have varying degrees of
affinity for different receptor combinations, resulting in activation of specific effector proteins in
order to mediate several signaling pathways. For example, TGF-β1 and TGF-β3 ligands primarily
bind to type II homodimer receptor complexes whereas TGF-β2 binding requires a type I/II
heteromeric complex. Type II TβRII activation of type I TβRI/ALK5 activates SMAD2/3 effector
proteins whereas activation of type I ALK1 receptor activates SMAD1/5 signaling [45]. The SMAD
pathway is discussed in further detail below.
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Canonical TGF-β signaling through SMADs
The most well-known and understood TGF-β effector pathway occurs through the
activation of SMAD proteins, also referred to as the TGF-β canonical pathway. There are eight
known SMAD proteins. Receptor-activated SMADs, or R-SMADs, include SMAD1, 2, 3, 5, and
8. SMAD2 and SMAD3 are the main effector proteins of the canonical TGF-β signaling pathway
and are activated through phosphorylation of its C-terminal domain by TβRI and activin receptor,
ActRIB. SMAD4 can form a heterotrimeric complex with SMAD2 and/or SMAD3 to facilitate
translocation into the nucleus to activate the EMT transcriptional program. Translocation of
SMAD2 and SMAD3 is mediated through a nuclear localization sequence recognized by
importin-β. Upon translocation into the nucleus, SMAD2 and SMAD3 interactions with the
CBP/p300 transcriptional coactivator and specific transcription factors, such as c-Jun, STAT3,
and LEF/TCF, in addition to their DNA-binding capabilities, allow for specific binding to promoter
regions and transcriptional activation of EMT-related genes [39, 45]. The majority of TGF-βmediated transcriptional activation of EMT is mediated through SMAD3-SMAD4 activity. Upon
ligand binding, TGF-β receptors are active for up to 4 hours; the longer the receptors remain
active, the longer R-SMADs remain in the nucleus to regulate gene transcription, including
activation of key EMT transcription factors such as SNAI, TWIST, and ZEB proteins [45]. SMADs
also activate expression of mesenchymal genes, including fibronectin, vimentin, and collagens
[25].
Regulation of SMAD proteins can be accomplished in several ways. SMAD6 and SMAD7
are inhibitory SMADs that repress R-SMAD signaling by competitively binding to the intracellular
domain of type I receptors to prevent R-SMAD phosphorylation [25, 39]. Inhibitory SMADs are
activated by TGF-β signaling, generating a negative feedback loop. SMAD7 can also recruit
SMAD ubiquitylation regulatory factor 1/2 (Smurf1/2), a member of the HECT family of E3
ubiquitin ligases, to type I receptors to induce receptor ubiquitination and proteasomal
degradation. Phosphorylated SMAD3 has been shown to interact with the SCF ubiquitin ligase
complex that facilitates SMAD3 nuclear exportation and ubiquitin-mediated degradation [45].
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Non-SMAD signaling and other inducers of EMT
In addition to SMAD-mediated signaling, TGF-β has been shown to activate RHO
GTPases, which mediate cytoskeletal changes during EMT. TGF-β also activates the PI3K/AKT
pathway to induce mTORC1 and mTORC2 proteins that are involved in motility and acquisition
of mesenchymal traits, respectively. Additionally, TGF-β signaling also contributes to activation
of MAPK pathways mediated by ERK, JNK, and p38 [25, 26, 39].
Aside from TGF-β signaling, there are several other pathways that can mediate induction
of EMT, including the PI3K/AKT and MAPK pathways. For example, RAS signaling has been
shown to induce expression of SNAI1/2 transcription factors and RHO GTPases [25]. FGF and
HGF signaling has also been demonstrated to initiate EMT through expression of SNAI proteins
[47]. Furthermore, other signaling pathways that have been implicated in regulating self-renewal,
stem cells, and play crucial roles during embryogenesis and development, such as Wnt, Notch,
and Hedgehog signaling, also induce an EMT [25, 26, 39, 48]. Wnt signaling inactivates the
destruction complex and inhibits GSK3β-mediated phosphorylation of β-catenin, which frees it
from its interaction with E-cadherin and α-catenin resulting in reduction of cell-cell adhesion [27].
Activation of Notch signaling through increased Jagged1 expression has been reported to induce
EMT through increased expression of the EMT transcription factor and master regulator, SNAI1,
and repression of E-cadherin expression [48].
There is also evidence of crosstalk between canonical TGF-β-SMAD signaling and other
pathways that mediate EMT. Activation of JNK by TGF-β can enhance SMAD3 nuclear
transportation and can lead to c-Jun-mediated cooperation with SMAD3 and SMAD4 complexes
in the nucleus and transcriptional activation [49]. RAS/MAPK signaling, although induces
production of TGF-β1, can phosphorylate SMAD3 to inhibit its translocation into the nucleus [44,
50]. As mentioned briefly, SMAD proteins can interact with the LEF/TCF transcription factors that
are stimulated in the context of Wnt signaling [51]. Activation of ERK can also phosphorylate and
activate SMAD2 for nuclear translocation [45].
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Transcription factors driving the EMT program
Several transcription factors are expressed in response to initiation of the EMT program,
most notably SNAI1/2, TWIST1/2, ZEB1/2, and FOXC2. These EMT-related transcription factors
regulate the expression of target genes that are involved in carrying out the transition process,
including repression of epithelial markers, polarity genes, and cell adhesion genes and
upregulation of mesenchymal markers and metalloproteases. Some transcription factors are also
involved in regulating the expression of each other. For example, ZEB1 gene is a direct target of
SNAI1 [25], and both transcription factors repress E-cadherin expression.
SNAI1 and SNAI2 have been shown to be highly active during all three types of EMTs
and can be activated through several EMT-inducing pathways, including TGF-β, Wnt, and Notch.
Both SNAI proteins are transcriptional repressors and contain a zinc-finger c-terminal domain
that binds to E-box sequences in promoter regions of target genes. SNAI1/2 can also modulate
gene expression through recruitment of histone modification complexes [25, 27]. SNAI proteins
are regulated via post-translational modifications that either affect their localization or
degradation. GSK3β, in the absence of Wnt signaling, can phosphorylate SNAI1 to mediate its
nuclear export and proteasomal degradation [25]. The tumor suppressor p53 has been
demonstrated to interact with SNAI2 and MDM2, resulting in ubiquitin-mediated degradation of
SNAI2 [52]. ZEB1 and ZEB2 also bind to E-box DNA sequences to mediate gene repression that
often involves a co-repressor called c-terminal binding protein (CTBP), and can be activated
through TGF-β, Wnt, and RAS signaling. Both SNAI and ZEB proteins are known for their role in
repressing E-cadherin expression. ZEB1 can also function as a transcriptional activator when it
is in a complex with the SMAD transcriptional coactivator CBP/p300 [25]. Members of the
microRNA family miR-200 regulate ZEB expression post-transcriptionally; miR-200a, b, and c
and miR-205 directly target ZEB1/2 mRNA [53]. TWIST1/2 are EMT-regulators but also mediate
cell differentiation [47] and are activated under hypoxic conditions through HIF1α. Similar to SNAI
proteins, TWIST proteins are regulated through post-translational modifications [25].
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EMT and carcinogenesis
TGF-β and EMT-related genes have been found to be upregulated in epithelial cancers,
as well as downregulation of E-cadherin, and correlated with increased tumor grade, prognosis,
and metastasis [33, 34, 54, 55]. Immunohistochemistry revealed high TWIST and SNAI2
expression in breast carcinomas. Increased SNAI1 expression in particular correlated with
increased tumor grade, metastasis, recurrence, and poor outcome [54]. A particular subset of
triple negative breast cancers is associated with a mesenchymal phenotype and express EMTrelated proteins, including vimentin, fibronectin and EMT transcription factors [56]. It was
discovered by Mani and colleagues that induction of the EMT program through overexpression
of EMT transcription factors or exposure to TGF-β generated mammary epithelial cells that have
acquired stem cell properties, including enhanced self-renewal and differentiation capacities,
expression of the CD44+/CD24- phenotype, and formation of in vitro mammospheres, a mass of
mammary cells that consists of stem, progenitor, and differentiated cells through an assay that
enriches for stem/progenitor cells in anchorage-independent conditions [57, 58]. This discovery
brings to light the question of whether EMT in the context of cancer can generate cancer stem
cells, thereby contributing to tumor heterogeneity and chemotherapy resistance.

1.3

Stem cells and cancer
The concept of a cancer cell of origin began in the 1930s by Furth and Kahn, who showed

that a single murine tumor cell could establish formation of a new tumor in a different mouse [59].
The stochastic evolution model was developed in the early 1970s and proposed that tumors arise
from a single cell that has acquired an array of genetic and molecular alterations that allow it to
proliferate uncontrollably and ignore growth inhibition signals. The alternative theory of cancer
stem cells as the cell of origin has been established for nearly five decades, beginning with
studies that demonstrated how teratomas, tumors developed from germ cells, generate
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differentiated cells of multiple cell types that follow a similar lineage path as a normal developing
germ cell [60].
Embryonic stem cells are undifferentiated cells that are capable of generating the three
germ layers and all cell types in the developing organism. Stem cells are capable of both
symmetric and asymmetric division; that is, they can self-renew and generate an identical stem
cell progeny or they can generate a daughter cell that exhibits a more lineage-restricted and
mature phenotype (multipotent progenitor, lineage-restricted progenitor, or differentiated cell)
[61]. In adulthood, there exist populations of stem cells that are capable of tissue regeneration in
the case of cell turnover or tissue damage. Stem cell populations have been identified and
isolated from intestinal crypts, bulge region of hair follicles, and stem cell niches of the skin and
mammary gland [62]. Stem cells isolated from the breast epithelium are able to generate a fully
functional mammary ductal system when transplanted into a cleared mammary fat-pad in mice.
Self-renewing stem cells are quiescent and rare. About 0.01% of bone marrow cells are believed
to be from a hematopoietic stem cell lineage [63] and may survive for extensive periods of time
compared to their more differentiated progeny. This longevity provides more possibilities of
incurring transforming mutations [64].
The theory of cancer stem cells as the target cell for carcinogenic transformation was
pioneered in the context of acute myeloid leukemia. Dick and colleagues demonstrated that there
is a rare population of CD34+/CD38- cells within the transformed hematopoietic cell hierarchy
with the ability to form tumors upon transplantation into immunocompromised NOD/SCID mice.
These rare cancer cells were able to generate differentiated progeny and self-renew, similar to
hematopoietic stem cells [65]. These carcinogenic stem-like cells are termed cancer stem cells
(CSCs) and have been isolated in solid tumors as well, including breast carcinomas [66]. Similar
to normal stem cells, CSCs have the ability to self-renew and give rise to differentiated progeny
[64, 67-69]. Progenitor cells, though unable to self-renew, could gain self-renewal capacity
through mutations and become a target for neoplastic transformation (Figure 1.2) [64].
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Figure 1.2: Cancer and normal stem cell characteristics. Normal stem cells can become
cancer stem cells through acquisition of mutations that would inhibit of apoptotic signals and
allow for uncontrolled growth. CSCs, like their normal counterparts, can self-renew and
asymmetrically differentiate to generate progenitor cells and mature differentiated cells that form
the bulk of the tumor. Several studies have now shown that mutations can occur that push mature
cells to become dedifferentiated, including initiation of the EMT process.
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The mammary ductal system is maintained by stem cells that are believed to reside in and
originate from the myoepithlial/basal cell population adjacent to the basement membrane and
can generate luminal or myoepithelial/basal cells that form branching ducts within the mammary
gland and end in terminal ductal-lobular units [70-72]. The interior of the ducts is composed of a
single layer of luminal epithelial cells encompassed by myoepithelial cells [71, 73]. Many studies
aimed to identify the putative stem and progenitor cell populations within the mammary gland
architecture. Several marker combinations have been used to classify distinct populations of
cells, including CD49f (α-6-integrin), which is expressed in cells located in the basal region;
epithelial cell adhesion molecule (EpCAM) that is expressed by cells in the luminal compartment
as well as cells in the underlying myoepithelial/basal region; mucin 1 (MUC1), a luminal cell
surface marker; and luminal- and basal-specific cytokeratins such as CK8/18 and CK14,
respectively. Putative stem and progenitor cell populations can also be identified based on cells’
ability to exclude Hoechst 33342, a fluorescent dye, through overexpression of ABC drug
transporters [71, 74, 75]. Al-Hajj and colleagues demonstrated that breast cancer stem cells
could be identified by a CD44+/CD24- surface adhesion marker phenotype sorted from Lineagenegative (Lin-) breast tumor cells; these cells, when injected at low density, formed tumors with
as few as 1,000 cells whereas CD44+/CD24+ cells were not able to form any tumors [66].
Furthermore, CD44+/CD24- cells proliferated to produce a heterogeneous population and
generated

CD44+/CD24-,

CD44-/CD24+,

and

CD44+/CD24+

cell

phenotypes

[76].

CD44+/CD24- cells have been shown to associate with poor overall survival and disease-free
survival [77] and are detected in basal-like and HER2 overexpressing breast tumors [78]. Another
widely used stem and progenitor cell marker is aldehyde dehydrogenase 1 (ALDH1), a retinoloxidizing enzyme that is expressed at high levels in both normal and breast cancer stem cells.
Injection of as few as 500 ALDH1+ invasive ductal carcinoma cells into cleared mouse mammary
fat-pads generated tumors [79]. Interestingly, there is little overlap between ALDH1+ and
CD44+/CD24- cells, but cells that are ALDH1+/CD44+/CD24- are highly metastatic and
aggressive compared to ALDH1+ or CD44/CD24- alone. Although each phenotype associates
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with metastasis in vitro and in vivo, CD44+/24- cells correlated with proliferative potential
whereas ALDH1+ correlated with migration and invasion [80].
Studies have now identified several signaling pathways deregulated in cancers that are
also associated with regulating stem cell self-renewal, such as Wnt, Notch, Hippo, Hedgehog,
and TGF-β signaling pathways [15, 64, 81-83]. In 2008, Mani et al. established a link between
induction of EMT and stem cell properties. It was demonstrated that immortalized human
mammary epithelial cells (HMLEs) forced to undergo EMT either through the overexpression of
master regulators of EMT or through exposure to TGF-β was sufficient to induce stem cell
phenotypes such as enhanced mammosphere formation, in vitro differentiation, and increased
CD44+/CD24- cell population. It was also observed that the existing population of stem cells in
HMLEs overexpressed mesenchymal markers, including N-cadherin and vimentin, and EMT
transcription factors, including SNAI1, ZEB2, and TWIST1 [57]. Other studies of EMT-related
transcription factors have confirmed a relationship between overexpression of master regulators
of EMT and a stem cell phenotype. Overexpression of TWIST in normal human mammary
epithelial cell line MCF10A and luminal breast cancer cell line MCF-7 generated breast epithelial
cells that could exclude Hoechst dye and increased the number of CD44+/CD24- cells through
the ability of TWIST to mediate CD24 transcriptional activity [84]. Interestingly, studies related to
TWIST and cancer stem cell properties revealed that TWIST-mediated stemness can be
independent of EMT [85]. Other EMT regulators, such as SNAI2, were also shown to play a large
role in dedifferentiation in vitro and in vivo [86-88]. Thus, transcription factors that mediate EMT
through global reprogramming of gene expression could allow for the acquisition stem cell
properties.

1.4

TRIM proteins and their roles in cancer
Tripartite motif (TRIM) proteins constitute a large family of proteins that contain a RING

finger, B-box, and coiled-coil domains, thus are also called RBCC proteins, and are involved in
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mediating protein-protein interactions and formation of large protein complexes. TRIM/RBCC
proteins have been demonstrated to play roles in a variety of cellular processes that include cell
growth, differentiation, cell death, gene expression, protein turnover, and viral immunity. There
are over 100 known TRIM proteins in mammals, which are categorized into subfamilies (C-I
through C-XI) based on their structural organization [89]. While there exists low sequence
homology between TRIM family members, the organization of the RBCC domains in the Nterminus are conserved: the RING finger domain begins 10-20 amino acid residues from the first
methionine and is followed by one to two B-box domains and a coiled-coil domain. The Cterminus is much more variable among TRIM proteins, though a few family members harbor
PRY/SPRY domains that are hypothesized to play roles in autoimmunity and viral restriction [9093].
The RING (Really Interesting New Gene) finger domain is formed by a sequence of
cysteine and histidine residues, binds zinc atoms, and is found on many E3 ubiquitin ligases,
such as BRCA1 and MDM2. E3 ubiquitin ligases are enzymes involved in the regulation of protein
activity and localization through their ability to ubiquitinate target proteins. E3 ligases mediate the
transfer of ubiquitin proteins from an E2 ubiquitin conjugating enzyme to target substrates,
specifically on the substrates’ lysine (Lys) residue. The exact location of the lysine residue
subjected to ubiquitin conjugation, as well as the number of ubiquitin moieties, play a crucial role
in determining protein fate: polyubiquitination of Lys-48 signals for 26S proteosomal degradation
whereas monoubiquitination or ubiquitination at Lys-63 controls protein localization and
activation/deactivation [89, 90, 94]. In addition to ubiquitin, E3 ligases have been demonstrated
to conjugate other ubiquitin-like moieties, including SUMO, Nedd8, and ISG15, to target
substrates to regulate their functions. This conjugation ability through the RING finger domain
allows TRIM proteins to regulate protein turnover, localization, activity, and gene transcription
through activation of histone modifiers and transcription factors [90, 95].
Following the RING finger domain is the B-box domain that also consists of a series of
cysteine and histidine residues and, similar to the RING finger domain, also binds zinc atoms. All
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TRIM proteins contain one to two B-box domains (labeled B-box1 and B-box2), and almost
always possess a B-box2 domain which is hypothesized to function in ubiquitination and binding
of DNA, RNA, and proteins. Following the B-box domain is always the coiled-coil domain that
mediates protein-protein interactions [90]. In addition to binding to target substrates for
ubiquitination, TRIM E3 ligases can ubiquitinate themselves or other TRIM proteins as a method
of self-regulation [89, 90].
There are several notable TRIM E3 ubiquitin ligases that play roles in carcinogenesis
through their involvement in the regulation of gene expression, cell proliferation and growth, and
apoptosis. Though the majority of TRIM proteins involved in tumorigenesis display oncogenic
properties, it was observed that their specific roles are context dependent. TRIM19, also known
as PML, is a tumor suppressor protein that generates PML nuclear bodies, a site at which
transcription, DNA damage repair, and replication occurs, and has been demonstrated to bind to
and inhibit MDM2 activity to stabilize p53 in the nucleus [89, 96]. However, the PML-RARα
(Retinoic Acid Receptor Alpha) fusion protein, observed in the majority of acute promyelocytic
leukemia patients, functions as a dominant negative protein that inhibits wild-type PML function
and localization [89]. More recently, in addition to its role in carcinogenesis, PML has been
identified as a regulator of pluripotency and stemness mediated through TBX3 and TGF-β
signaling and binds stem cell regulators including OCT4 and c-Myc [97, 98]. An earlier study also
identified PML as a regulator of luminal progenitor cell populations mediated through STAT3 and
STAT6 [99].
Members of the TIF1 family, such as TRIM24 and TRIM28, are overexpressed in breast
and gastric cancers, respectively, and are associated with poor prognosis. TRIM24 harbors a
PHD finger domain and bromodomain that mediates interaction with chromatin remodeling
nuclear proteins and, similar to TRIM19, can interact with RARα and often undergoes fusion with
other proteins. The TRIM24-FGFR1 fusion protein contains TRIM24’s RBCC domain and
FGFR1’s tyrosine kinase domain, allowing for constitutive activation of FGFR1 that promotes
transformation. However, TRIM24 seems to function as a tumor suppressor specifically in hepatic
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cancer, as homozygous deletion of Trim24 in mice resulted in increased incidence of tumors in
the liver [89].
TRIM27, also known as RFP (RET Finger Protein), is another TRIM protein that seems
to have both oncogenic and tumor suppressive functions. While studies have shown that TRIM27
potentially interacts with the PML-RARα fusion protein, is overexpressed in multiple cancer cells,
and correlates with ERBB2 expression in breast carcinomas, it was also demonstrated to
promote apoptosis. TRIM32, a regulator of miRNA biogenesis and neural differentiation, also
demonstrates polar roles in carcinogenesis. Its tumor suppressive function is suggested through
its mediation of TNF (tumor necrosis factor) –induced apoptosis. However, several reports of its
overexpression in squamous cell carcinomas suggest that it could act as an oncogene [89].
Several TRIM proteins have also been shown to mediate the activity and stability of wellknown tumor suppressor, p53. TRIM19 and TRIM13 function to stabilize p53 through the
inhibition of its main regulator, MDM2 (Mouse Double Minute 2). TRIM24, TRIM27, TRIM28, and
TRIM29 negatively regulates p53 through various mechanisms; TRIM24 binds to an ubiquitinates
p53, TRIM27 and TRIM28 stabilize MDM2 to promote p53 ubiquitination, and TRIM29 mediates
p53 inhibition through its transport out of the nucleus [89].
It is quite clear that TRIM E3 ubiquitin ligases play a major role in carcinogenesis, largely
through their abilities of controlling the activity, stability, and expression of other tumor
suppressor and tumor-promoting proteins. In the next section, I will report on another TRIM
protein, TRIM62 (also known as DEAR1 – Ductal Epithelium-Associated RING Chromosome 1),
which has been shown to be a major regulator of acinar-morphogenesis and cell polarity, and
negative regulator of TGF-β-mediated EMT.

1.5

Ductal Epithelium-Associated RING Chromosome 1 (DEAR1)
Ductal Epithelium-Associated RING Chromosome 1 (DEAR1) is a tumor suppressor gene

discovered in the Killary Lab and identified through suppression subtractive hybridization that
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Figure 1.3: Illustration of DEAR1 gene, protein, and mutation residues. The DEAR1 gene
encodes a protein product that contains five domains and has sequence similarities to the family
of TRIM E3 ubiquitin ligases. Sequence analysis revealed that DEAR1 undergoes an array of
mutations across all five domains, the majority of which are non-synonymous mutations, in
various cancer types. Permission was given to use this figure from Nanyue Chen et al, “DEAR1
is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-beta-Driven EpithelialMesenchymal

Transition”.
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resulted in a partial cDNA sequence that mapped to Chromosome 1p35.1, a region that resides
in the 1p interval that frequently undergoes loss of heterozygosity (LOH) in epithelial cancers,
including breast carcinoma [4]. Sequencing revealed that DEAR1 shares sequence similarities
to the TRIM/RBCC protein family, thus DEAR1 is also annotated as TRIM62. The DEAR1 gene
encodes a 475 amino acid protein predicted to be 54kDa in size and harbors 5 domains: RING
finger, B-box2, coiled-coil, PRY, and SPRY domains (Figure 1.3) [100]. Studies in our lab and
by Huang et al. demonstrates that DEAR1 has E3 ubiquitin ligase activity and localizes in the
cytoplasm; it has also been shown that DEAR1 has the ability to self-polyubiquitinate in HEK293T
cells and that the ligase activity is dependent on the RING domain [101]. DEAR1 is expressed in
normal glandular epithelium of tissues such as the bladder, kidney, breast, and prostate. In a
cohort of 14 DCIS samples with associated normal and invasive ductal carcinoma samples,
DEAR1 protein was highly expressed in the normal mammary epithelium but its expression is
downregulated in 71% of cases; 50% of the 10 cases with associated IDC also showed loss of
expression of DEAR1. DEAR1 expression was demonstrated to be downregulated in 75% of
breast cancer cell lines assayed, including two lines of the 21T series derived from a 36 year-old
female with invasive ductal adenocarcinoma. Sequencing of three cell lines derived from the 21T
series revealed that all three harbored a non-conservative missense mutation, R187W, which
maps to the third exon that encodes the coiled-coil domain that is predicted to mediate proteinprotein interactions [100].
Functional assays were performed using 3D matrigel culture to assess the importance
and relevance of the R187W mutation, as well as expression of DEAR1, in acini formation and
pathogenesis. The 21MT cell line that harbors the R187W mutation formed large, disorganized,
multi-acinar structures when plated in 3D matrigel. By expressing the wildtype (WT) DEAR1
protein, the mutant phenotype was rescued and the 21MT cells were able to form proper acini
similar to those formed by normal immortalized human mammary epithelial cells (HMECs).
Staining of the acini revealed that the acinar structures formed from 21MT cells have
disorganized expression of E-cadherin and α-6-integrin, which is a marker of proper polarity
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signal. Ki67 staining suggests that DEAR1 does not influence proliferation but rather apoptosis
as shown by active Caspase 3 staining. These experiments were also carried out in MCF-7
breast cancer cells, which do not express detectable DEAR1 protein, and results were similar to
what was demonstrated in 21MT cells. To further demonstrate that DEAR1 expression is
important for the regulation of proper acini formation, lentiviral shRNA knockdown (KD) of DEAR1
was performed on immortalized HMECs. Results showed that when DEAR1 expression is lost,
cells were unable to form normal acini in matrigel following 16 days of culture in contrast to control
HMECs, which formed proper acini. These irregular acini showed loss of apical-basal polarity as
demonstrated by improper expression of α-6-integrin [100].
These initial studies that aimed to characterize DEAR1 and ascertain its function revealed
that DEAR1 is a crucial regulator of apical-basal polarity and its expression is necessary for
proper acinar morphogenesis. Data from the DEAR1 knockout mouse model suggests that
DEAR1 is a bona fide tumor suppressor. DEAR1 hetero- and homozygous knockout (KO) mice
formed late onset tumors in 12.9% and 17.7% of cases, respectively, whereas only 4% of DEAR1
WT mice developed tumors. DEAR1-KO mice developed adenocarcinomas in multiple organs
including mammary, pancreatic, lung, and liver, as well as sarcomas and lymphomas.
Interestingly, DEAR1 heterozygous mice developed tumors with a similar frequency as DEAR1
homozygous knockout mice, suggesting that DEAR1 might function as a haploinsufficient tumor
suppressor [102].
Since loss of cell polarity is strongly associated with early steps in initiating EMT, it was
postulated that DEAR1 may also play a role in mediating the EMT process. Western blot analysis
indicated that loss of DEAR1 in the presence of TGF-β resulted in increased mesenchymal
phenotypes, as indicated by increased expression of Vimentin and N-cadherin. DEAR1-KD
clones in the presence of TGF-β exhibited increased cell motility as assayed through migration
assays in matrigel. Scratch wound assays confirmed that loss of DEAR1 after treatment with
TGF-β resulted in rapid wound closure compared to untreated WT and KD cells. Through co-IP
experiments, it was demonstrated that DEAR1 binds to SMAD3, a crucial coeffector protein in
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the canonical TGF-β pathway, and results in polyubiquitination of SMAD3. DEAR1 and SMAD3
expressions are inversely correlated in the DEAR1 knockout mouse model, as well as in human
breast tumors. In vitro assays revealed that DEAR1 KD resulted in increased phosphorylated
SMAD3 in the presence of TGF-β and SMAD3 levels are reduced in DEAR1 overexpressing
MCF-7 cells. These experiments show that in addition to its role in regulating cell polarity and
acinar morphogenesis, DEAR1 is also a negative regulator of TGF-β-mediated EMT through the
inhibition of SMAD3 (Figure 1.4) [102, 103].
In addition to the R187W mutation, DEAR1 was shown to harbor mutations in a variety
of carcinomas that are associated with Chromosome 1p LOH, such as lung squamous cell,
pancreatic, and renal carcinomas, and these mutations can be found across all five domains
(Figure 1.3) [102]. Deep sequencing revealed that DEAR is mutated in 71% of pure DCIS and
DCIS with microinvasive lesions. Approximately 8% of the variants in pure DCIS were found
within exonic regions, the majority of which were not reported in variant databases [Reuther, in
preparation]. The D106V variant was shown to enhance the transcriptional activity of SMAD3
compared to wildtype DEAR. Functional assays utilizing SKRB3 breast cancer cell line, which
does not express detectable levels of DEAR1 protein, were performed to study the effects of the
variants. Results indicated that while expression of wildtype DEAR1 allowed for proper acini
formation, cells expressing the R254Q variant were unable to form acini, similar to that of the
R187W mutation previously discussed [Reuther, in preparation].
Since DEAR1 is mapped to a region that is frequently observed to undergo LOH in
epithelial cancers and copy number alterations (CNA) in breast, lung, pancreatic, and colorectal
cancers, its expression status may be of value for determining prognosis in cancer patients.
DEAR1 expression was screened in a cohort of 158 stage I/II breast cancer patients who have
had breast conservation surgery followed by radiotherapy between the ages of 25-49 years.
Approximately 56% of these samples demonstrated loss of DEAR1 expression. Although DEAR1
loss did not correlate with ER or HER2 status, tumor size, metastasis, or BRCA1/2 mutations,
loss of DEAR1 expression correlated with family history of breast cancer, PR-negative tumors,
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Figure 1.4: Illustration of DEAR1 regulation of cell polarity and EMT. DEAR1 functions as a
master regulator of acinar morphogenesis through regulation of apical-basal cell polarity, an
important aspect of maintaining cellular architecture. DEAR1 also negatively regulates EMT
through the canonical TGF-β signaling pathway by polyubiquitinating effector signaling protein,
SMAD3, and signaling for proteasomal-mediated degradation, thus limiting the availability of
SMAD3 to translocation into the nucleus to transcriptionally activate EMT-related genes. In the
absence of DEAR1, through loss of function mutations or loss of expression, SMAD3 is
phosphorylated and activated in the presence of TGF-β and an EMT occurs.
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and the triple negative phenotype. DEAR1 loss of expression also significantly predicted local
recurrence. At a 5-year follow-up, DEAR1 expression correlated with a 95% local recurrencefree survival, which remained consistent over the course of a 15-year follow-up. However, tumors
that had loss of expression demonstrated a drop in recurrence-free survival to 58% after 15 years
of follow-up [100].
Other studies in different cell types confirm what the Killary Lab has reported on DEAR1
and its role in the initiation and progression of cancer. In a study by Quintás-Cardama et al.,
DEAR1 was shown to be expressed in immortalized normal bronchial epithelial cells but loses
expression in 66% of non-small cell lung cancer (NSCLC) cell lines tested and 86% of NSCLC
tumors (n=214). A separate cohort of 72 NSCLC patients demonstrated DEAR1 loss of
expression in 62% of tumor samples. Patients with low DEAR1 staining relapsed at a significantly
faster rate compared to patients with high DEAR1 staining (5.1 v 2.87 years, p=0.049). Using a
DEAR1-deficient K-RasLA1 mouse model, this study showed that compound mutant mice
experienced reduced lifespans and a higher number of lung tumors compared to that of K-Ras
and p53+/--K-Ras mutant mice and identified DEAR1 as a haploinsufficient gene that synergizes
with K-RasG12D mutation to promote invasion and metastasis in the context of lung
adenocarcinomas [104]. Another study in acute myeloid leukemia showed that loss of DEAR1
expression correlated with poor overall survival and shorter disease-free survival in acute
myeloid leukemia compared to healthy controls [105, 106].
A study on certical cancer by Liu and colleagues demonstrated that DEAR1 expression
is reduced in early stage cervical cancer samples, correlated with tumor size, recurrence,
differentiation grade, and is downregulated in cervical cancer cell lines. Experiments using SiHa
and HeLa, cervical cancer cell lines that do not express detectable levels of DEAR1 protein,
revealed that overexpression of DEAR1 resulted in inhibition of proliferation, colony formation,
migration, invasion, tumor growth, and pulmonary metastases. The authors identified a negative
correlation between DEAR1 expression and MAPK/JNK signaling and demonstrated that
overexpression of DEAR1 results in repression of c-Jun and its downstream transcriptional
28

targets such as SNAI2 and Cyclin D1. This study identified another pathway involved in tumor
initiation and progression potentially regulated by DEAR1 in the context of cervical cancer [107].
In addition to its role in cancer, DEAR1 was shown to mediate immunity through induction
of NF-κB signaling that requires the RING, B-box and coiled-coil domains [108, 109]. A study by
Cao et al. identified CARD9, a mediator of cytokine production and T-cell response, as a target
of DEAR1 ubiquitination that is dependent on DEAR1’s RING domain. This study discovered that
ubiquitination of CARD9 at the Lys125 residue is crucial for CARD9 activity and that abrogation
of CARD9-DEAR1 interaction through loss of DEAR1 or CARD9 small molecule inhibitor, results
in repression of CARD9 signaling, inhibition of cytokine production and signaling, and
susceptibility to infection [108, 110].
The data collected thus far indicate that DEAR1 is a bona fide Chromosome 1p tumor
suppressor that undergoes mutation, copy number alterations, and loss of expression in a variety
of epithelial cancers, including breast cancer. Evidence indicates that DEAR1 plays an important
role in maintaining cell polarity, regulating acinar morphogenesis, and negatively regulating the
TGF-β-mediated EMT program and may play a critical role in inhibiting tumor initiation and
progression. Since loss of DEAR1 releases the inhibitory effect on TGF-β-mediated EMT, which
has now been shown to confer stem cell properties in both normal and cancer cells, I hypothesize
that DEAR1 may also regulate stem and/or progenitor cell properties. Results herein
demonstrate that DEAR1 regulates progenitor cell phenotypes in both the absence and presence
of TGF-β signaling and identifies a novel regulatory mechanism of the EMT and stemness
regulator, SNAI2, through DEAR1 that is independent of the canonical TGF-β pathway, which
may play a role in mediating the stem cell-like phenotype. Additionally, I provide preliminary data
that suggests DEAR1 expression may be regulated by microRNAs, specifically miR-10b and
miR-196b.
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CHAPTER 2: Loss of DEAR1 confers stem and/or progenitor cell properties
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2.1

Introduction
Several groups have demonstrated the link between EMT initiation and the acquisition of

stem cell properties in human breast cells. This discovery was pioneered by Mani and colleagues
when they observed that HMLEs forced to undergo EMT through overexpression of EMT
regulators SNAI1 and/or TWIST1 or exposure to TGF-β resulted in enhanced mammosphere
formation, in vitro differentiation capabilities, and a greater number of CD44+/CD24- expressing
cells. When HMLE cells were sorted based on CD44 and CD24 surface marker expression, the
CD44+/CD24- population showed higher expression of mesenchymal markers and EMT markers
and transcription factors, including vimentin, fibronectin, SNAI1, and ZEB2 compared to their
CD24+ counterparts. Furthermore, the sorted CD44+/CD24- cells were the only cells capable of
generating mammospheres. It was also demonstrated that H-Ras transformed HMLEs (HMLER
cells) undergoing an EMT were able to generate tumors in cleared mouse mammary fat-pads
when injected at low densities, providing evidence that EMT can induce a cancer stem cell
phenotype [57, 76]. Morel et al. used HMLER cells to demonstrate that initiation of EMT or
activation of MAPK can induce generation of a larger population of CD24- cells and showed that
CD24+ cells can be converted to CD24- cells through exposure to TGF-β [76].
The mammosphere assay is an in vitro protocol that was derived from the neurosphere
assay first established by Reynolds and Weiss in 1996 [111] to functionally identify stem and/or
progenitor cells. Cells grown in 2D culture are dissociated into single cells and plated on ultralow attachment plates in Mammary Epithelial Cell Growth Medium (MEGM) supplemented with
EGF, hFGF, and heparin. Cells able to survive and proliferate in the low adherent condition are
expected to have stem/progenitor cell properties and form spheres, termed “mammospheres”,
that are comprised of stem, multipotent and/or bipotent progenitor, and differentiated cells
(Figure 2.1) [58, 112, 113]. The mammosphere assay can also be used to study self-renewal
and differentiation capacity, two noteworthy characteristics of normal stem cells. An in vitro assay
to demonstrate self-renewal capacity is through serial passaging of primary mammospheres for
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Figure 2.1: Mammosphere assay. The mammosphere assay is an in vitro method of enriching
for cells with stem or progenitor cell properties, which are capable of surviving and proliferating
in non-adherent conditions. Mammary epithelial cells grown in 2D culture are dissociated and
plated in ultra-low attachment plates in MEGM supplemented with EGF, FGF, and heparin.
Mammospheres are spheres of cells that consist of stem or progenitor cells and differentiated
progeny. Mammosphere forming efficiency (MFE) is calculated as a percentage by counting the
number of mammospheres larger than 50μM divided by the number of cells seeded, multiplied
by 100. The MFE range for normal mammary epithelial cells is 0.1-7% whereas the MFE for
breast cancer cell lines is 1-3%. Primary mammospheres could be serially passaged to generate
secondary and tertiary mammospheres to determine self-renewal capacity and stained to study
differentiation marker expression to evaluate differentiation capacity [58].
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n generations. Over time, cells with the ability to self-renew would generate an increasing number
of mammospheres upon re-plating. Progenitor cells, which do not have self-renewal capacities
but have higher proliferation potential, would result in the generation of larger mammospheres
but serial passaging would result in a decrease in mammosphere quantity over time [58, 112,
114]. In vitro differentiation assays include flow cytometry sorting based on combinations of
epithelial surface markers to determine changes in population of different epithelial lineages,
immunofluorescence staining of mammospheres using luminal and basal cytokeratin markers,
and colony forming assays to identify multipotent progenitor cells [57, 58, 70, 114]. An in vivo
method to test for stemness is through a limited dilution assay in which different densities of cells
are injected into cleared mammary fat-pads. At low density, cells with self-renewal potential and
differentiation capacity can regenerate the mammary ductal system. This method has also been
utilized to test the identity of cancer stem cells [57, 58, 79, 115].
Although DEAR1 has been demonstrated to be a bona fide tumor suppressor in breast
carcinoma, its specific role in carcinogenesis and biological pathways remains unclear. Given
that DEAR1 is a regulator of acinar morphogenesis through its control of apical-basal cell polarity
[100] and is a negative regulator of EMT initiation through the canonical TGF-β pathway by
binding and polyubiquitinating SMAD3 [102] and that EMT has been directly linked to the
acquisition of a stem cell phenotype in immortalized human mammary epithelial cells, I
hypothesize that DEAR1 could play a role in mediating the acquisition of stem cell properties.
Using the mammosphere assay described above, I present data indicating that loss of DEAR1
expression in human mammary epithelial cells and DCIS cells enhances stem/progenitor cell
properties.

2.2

Results
Utilizing stable DEAR1 KD MCF10A cells, a commonly used spontaneously immortalized

non-tumorigenic human mammary epithelial cell line, I observed that loss of DEAR1 (DshR)
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resulted in a significant increase in mammosphere quantity compared to control vector cells
(CshR) (DshR 23.11±5.18 vs CshR 6.125±2.75, p<0.0001, Figure 2.2). Stable DEAR1 KD in
another immortalized, non-tumorigenic mammary epithelial cell line, 76N-E6, produced
significantly greater numbers of primary mammospheres compared to control vector cells (DshR
11.875±7.63 vs CshR 0.96±1.60, p<0.0001). When 76N-E6 cells are treated with 4ng/mL TGFβ for 48 hours prior to plating for mammopsheres, all three DEAR1 KD clones formed significantly
more mammospheres compared to TGF-β-exposed control vector cells (DshR 28.36±12.21 vs
CshR 4.91±3.22, p<0.0001, Figure 2.3A & C).
We previously showed that DEAR1 binds specifically to SMAD3 and promotes its
polyubiquitination. DEAR1-SMAD3 double KD HMECs were demonstrated to rescue the
mesenchymal phenotype presented in DEAR1 KD HMECs. To determine if the mammosphere
phenotype is dependent on SMAD3 signaling, we plated non-treated and TGF-β-treated DEAR1SMAD3 double KD 76N-E6 cells in mammosphere growing conditions. In the absence of TGF-β
exposure, DEAR1-SMAD3 double KD 76N-E6 cells generated as many mammospheres as
DEAR1-KD cells (DshR-shSM3 19.46±6.95 vs DshR 17.92±10.75, p-value=0.56, Figure 2.4A &
C). In the presence of TGF-β signaling, we observed that DEAR1-SMAD3 double KD 76N-E6
cells formed significantly fewer primary mammospheres compared to DEAR1 KD alone (DshRshSM3 15.25±4.91 vs DshR 30.13±10.01, p<0.0001, Figure 2.4A & C). This data suggests that
the mammosphere phenotype mediated by loss of DEAR1 is partially dependent on SMAD3
expression since we observed partial rescue of the mammosphere phenotype in DEAR1-SMAD3
double KD cells in the presence of TGF-β. However, since the average number of primary
mammospheres formed by DEAR1-SMAD3 double KD 76N-E6 cells was similar to that of
DEAR1 KD alone in the absence of TGF-β signaling, we believe that loss of DEAR1 alone
contributes to the mammosphere phenotype independent of the TGF-β-SMAD3 axis. To confirm
that mammospheres formed by HMEC clones are enriched for stem-like cells, whole spheres
were harvested and fixed onto glass microscope slides for immunofluorescence staining.
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Figure 2.2: Mammosphere formation in MCF10A cells. A preliminary mammosphere assay
using immortalized human mammary epithelial cell line MCF10A reveals stable DEAR1-KD
results in increased number of primary mammospheres. MCF10A control vector and DEAR1-KD
pools were grown in 2D culture and plated in mammosphere-growing conditions (1000 cells/well
in an ultra-low attachment 96-well plate). After 14 days, mammospheres larger than 50μM were
counted. DEAR1-KD MCF10A cells formed significantly more cells compared to control vector
cells (****p<0.0001).
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Figure 2.3: Stable DEAR1-KD in HMECs results in increased mammosphere number and
size in the presence of TGF-β. A) Two control vector clones (CshR) and three DEAR1-KD
clones (DshR) were grown in 2D culture in two conditions: non-treated and treated (4ng/mL TGFβ for 48h). Cells grown in 2D were trypsinized and plated in 96-well ultra-low attachment plates
at 1000 cells/well density. The bar graph represents the average number of primary
mammospheres formed from each cell line and condition across three trials. In the non-treated
cohort, two DEAR1-KD clones formed significantly more mammospheres compared to control
vector cells. In the presence of TGF-β, all three DEAR1-KD clones formed significantly more
spheres compared to treated control vector cells. Statistical analysis was performed using oneway ANOVA multiple comparison (compared to CshR1). B) Western blot analysis shows that
DEAR1 expression is reduced in DEAR1-KD HMECs. C) Average number of primary
mammospheres generated by control vector and DEAR1-KD HMEC clones in each trial and
corresponding p-values. DEAR1-KD HMECs grown under TGF-β exposure form more primary
mammospheres compared to treated control vector HMECs. D) HMEC mammospheres larger
than 50uM were counted using a Zeiss microscope. Images were taken at 10X magnification.
This assay was performed in triplicate, and data presented represents the average number of
mammospheres across all three trials. P-value ***<0.001, ****<0.0001.
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Figure 2.4: Increased primary mammosphere formation in DEAR1-KD HMECs is partially
dependent on SMAD3 signaling in the presence of TGF-β. A) Untreated DEAR1-KD cells
formed significantly more primary mammospheres compared to untreated control vector cells;
untreated DEAR1-SMAD3 double KD did not show a significant difference in mammosphere
quantity compared to DEAR1-KD alone. However, in the presence of TGF-β signaling, DEAR1SMAD3 double KD cells formed significantly fewer mammospheres compared to loss of DEAR1
alone, suggesting that the mammosphere phenotype is dependent on SMAD3 signaling only in
the context of TGF-β exposure. B) Western blot analysis confirms DEAR1 KD in HMECs and
loss of SMAD3 expression in the DEAR1-SMAD3 double KD clone. C) Average number of
primary mammospheres generated by control vector and DEAR1-KD HMEC clones in each trial
and corresponding p-values. DEAR1-SMAD3 double KD HMECs grown under TGF-β exposure
consistently form fewer primary mammospheres compared to DEAR1-KD HMECs. D) HMEC
mammospheres larger than 50uM were counted using a Zeiss microscope. Images were taken
at 10X magnification. This assay was performed in triplicate, and data presented represents the
average number of mammospheres across all three trials. P-value ****<0.0001.
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ALDH1 is an established marker for stem and progenitor cells, and is overexpressed in both
normal and cancer stem cells [79]. ALDH1 expression is barely detectable in HMEC clones grown
in 2D culture conditions (Figure 2.5A). However, HMECs grown in 3D mammosphere conditions
result in high expression of ALDH1 (Figure 2.5B), indicating that in our 3D HMEC mammosphere
assay, cells with stem and/or progenitor properties are enriched and importantly, that loss of
DEAR1 results in a higher number of cells with stem and/or progenitor properties as
demonstrated by the increase in the number of mammospheres formed by DEAR1 KD clones.
Stem cells are distinguished from other cell types through their ability to self-renew
(forming more stem cells) and to differentiate into other cell types (multipotent progenitor cells,
bipotent progenitor cells, and mature differentiated cells) [58, 113, 114]. In order to determine if
loss of DEAR1 contributed to self-renewal in our HMEC model, primary mammospheres were
passaged by disseminating spheres into single cell suspensions and re-plated at the same
density to form secondary and tertiary mammospheres. According to Dontu et al., the number of
spheres should increase after multiple passages if there are stem cells, which have the ability to
generate more stem cells, in the population [58]. I observed that loss of DEAR1 in HMECs did
not allow for the acquisition of self-renewal capabilities, even in the presence of TGF-β signaling,
as indicated by the unaltered or reduced fold-change (DshR 0.59±0.94 vs CshR 1.08±0.55,
p=0.55, Figure 2.6).
Another well-known characteristic of stem and progenitor cells is the ability to differentiate
into other cell types. There are two types of differentiated mammary epithelial cells that can be
generated by mammary bipotent progenitor cells: luminal and myoepithelial/basal cells. To
determine if DEAR1 loss could promote bipotential capacity, or the capacity to differentiate into
either luminal or myoepithelial/basal lineages, primary mammospheres were fixed onto
microscope slides and stained by immunofluorescence staining for cytokeratin (CK) 8/18, a
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Figure 2.5: ALDH1 expression in 2D and 3D mammosphere culture. ALDH1, a marker of
normal and cancer stem cells, is expressed in HMEC cells grown in mammosphere conditions,
but not in 2D culture. A) 76N-E6 control and DEAR1-KD clones were grown in 2D culture in the
absence of TGF-β. When grown in these conditions, expression of ALDH1 is minimal (white
arrows). B) When 76N-E6 control and DEAR1-KD clones were grown in mammosphere
conditions, ALDH1 was highly expressed in mammosphere-forming cells, even in the control
mammospheres. A similar trend was observed when cells were grown in either 2D or 3D
mammosphere culture in the presence of TGF-β signaling (C&D). These results indicate that the
mammospheres formed using this assay are enriched for stem- or progenitor-like cells. Images
were taken at 10X magnification.
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Table 2.1: Loss of DEAR1 in HMECs does not confer self-renewal potential. Untreated and
TGF-β-treated primary mammospheres were dissociated into single-cell suspensions and replated in mammosphere growing conditions to generate secondary mammospheres. One
DEAR1-KD clone (DshR1) was able to generate more secondary mammospheres in the
untreated cohort, however this data could not be replicated in other trials. All other clones did not
demonstrate self-renewal capacities. This indicates that loss of DEAR1 does not affect selfrenewal capacities in HMECs. Self-renewal assays were performed in three independent trials.
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luminal cell surface marker, and CK5, a myoepithelial/basal cell surface marker [15, 62, 77].
When stained for these surface markers, I observed a population of cells within the
mammospheres that co-express both CK8/18 and CK5, suggesting that these cells have
bipotential capacity [57], but did not demonstrate a significant difference in the number of bipotent
cells between CshR and DshR clones (no treatment p=0.25, Figure 2.7A; TGF-β p=0.083,
Figure 2.7B). FACS analysis using EpCAM and CD49f (α-6-integrin) revealed that when DEAR1
expression is lost in HMECs, there is a significant shift in the percentage of cells in the
EpCAM+/CD49f+ population, indicative of luminal progenitor/differentiated cells, to a EpCAM/low

/CD49f+ phenotype, indicative of basal progenitor and/or bipotent cells [73, 88, 115], in two

DEAR1 KD clones (DshR 3.82%±2.50 vs CshR 0.54%±0.28, p=0.04, Figure 2.8A&B).
Furthermore, a FACS analysis by Dr. Nanyue Chen, an Assistant Professor in our laboratory,
using CD44 and CD24 surface markers revealed that DEAR1-KD clones have a higher
CD44:CD24 ratio compared to control vector clones due to loss of CD24 expression (DshR
45.22±22.59 vs CshR 95.88±19.12, p=0.01, Figure 2.8C). Together, this data suggests that
although loss of DEAR1 may not result in a stem cell phenotype, loss of DEAR1 can affect
progenitor cell properties and regulate basal cell fate.
To study if loss of DEAR1 in a different mammary epithelial cell line results in acquisition
of a stem/progenitor cell phenotype, we utilized MCF10DCIS.COM cells (DCIS.COM), a cell line
derived from MCF10A cell line series that generates necrotic DCIS lesions when injected into
immunocompromised mice [116-119]. DCIS.COM cells express high levels of DEAR1, thus we
knocked down DEAR1 expression using the GIPZ-GFP shTRIM62 lentiviral vectors from
Dharmacon to ascertain any effects on the mammosphere phenotype. Two control vector clones
(CshR-7 and CshR-20) and one DEAR1-KD clone (DshR 9-7) were selected based on protein
and mRNA expression (Figure 2.9A). Results show that the number of primary mammosphere
formed by control vector and DEAR1-KD clones were not consistently significantly different when
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Figure 2.7: Mammospheres contain bipotent cells. 76N-E6 control and DEAR1-KD clones
grown in 3D mammosphere culture in the absence (A) or presence (B) of TGFb were stained
using luminal and myoepithelial/basal cytokeratin surface markers, CK 8/18 and CK 5,
respectively. All four categories of mammospheres contained a small population of cells that coexpress both CK8/18 and CK5 (white arrows). Images were taken at 20X magnification.
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Figure 2.8: DEAR1-KD HMECs contain a larger population of basal-like cells. A&B) WT and
DEAR1-KD HMECs were sorted based on expression of EpCAM and CD49f surface markers.
Previous studies have categorized epithelial cells into distinct lineages based on surface marker
expression profiles. EpCAMhi/CD49f+ signifies mature luminal cells while EpCAMhi/CD49+ are
luminal progenitor cells; EpCAMlo/CD49f+ cells are categorized as mature basal cells and
EpCAM-/CD49f+ as basal progenitor cells. FACS data revealed that loss of DEAR1 expression
HMECs generates a significant increase in the population of basal mature and progenitor cells
that are EpCAMlo/-/CD49f+. C) FACS data indicates that there is significant repression of CD24
surface marker expression in both DEAR1-KD clones compared to control vectors. P-value
**<0.01, ****<0.0001.
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plated at a density of 500 cells/well (DshR 43±10.64 vs CshR 40.56±10.3, p=0.60), however we
observed a consistent significant increase in the average size of mammosphere formed by the
DEAR1-KD DCIS clone (DshR 112.09uM±31.60 vs CshR 77.27uM±17, p<0.0001, Figure 2.9B)
when plated at a density of 1000 cells/well. Dr. Nanyue Chen also generated DEAR1 knockout
(KO) DCIS clones. With his permission, I used these clones and respective wildtype control
clones to test mammosphere formation. Similar to the KD experiments, knockout clones did not
consistently form more primary mammospheres compared to controls (KO 63.67±14.8 vs WT
56.96±12.16, p=0.59, Figure 2.10A). Results indicated that, on average, DEAR1-KO DCIS
clones consistently formed larger mammospheres compared to DEAR1-expressing DCIS clones
(KO 113.02uM±52.93 vs WT 82.96uM±20.66, p<0.0001) and that all clones formed at least one
or more mammosphere(s) larger than 150uM (Figure 2.10B). Mammosphere size has been
previously correlated with progenitor cell population [58, 112]. DCIS primary mammospheres
were serially passaged to form secondary and tertiary mammospheres. All cell lines could be
propagated as secondary and tertiary spheres, but DEAR1-KO mammospheres continued to
form larger mammospheres compared to DCIS WT mammospheres (KO 134.8uM±58.19 vs WT
98.99uM±28.61, p<0.0001, Figure 2.11A&B). DEAR1 knockout in DCIS cells, however,
demonstrated a different phenotype when exposed to TGF-β compared to the phenotype caused
by loss of DEAR1 in HMECs. Using two control and two DEAR1-KO DCIS clones, cells were
plated and treated with DMSO, TGF-β inhibitor, TGF-β, or both TGF-β and inhibitor. As shown
in Figure 2.12A, treatment with TGF-β inhibitor resulted in an increase in mammospheres in all
clones while treatment with TGF-β resulted in significant inhibition of the number of primary
mammospheres in control clones (treated 17.17±5.6 vs untreated 63.83±14.99, p<0.0001) and
reduction of primary mammospheres formed by DEAR1-KO clones, though not at a significant
level (treated 59±4.73 vs untreated 71.67±7.58, p=0.2). However, TGF-β-treated DEAR1-KO
clones formed significantly more mammospheres compared to TGF-β-treated control clones (KO
59±4.73 vs WT 17.17±5.6, p<0.0001). There was not a significant difference in size between
TGF-β-treated DEAR1-KO and control DCIS clones (KO 104.86uM±42.60 vs WT
48
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Figure 2.9: DEAR1 knockdown in DCIS.COM cells results in generation of significantly
larger primary mammospheres compared to control vectors. A) Stable DEAR1-KD and
control vector DCIS clones were generated using Dharmacon lentiviral shRNA vectors. DEAR1
loss was confirmed by western blot analysis and qPCR. B) DCIS clones were plated in
mammosphere growing conditions at either 500 or 1000 cells/well densities. DEAR1 KD did not
increase primary mammosphere quantity, however at 1000 cells/well, DEAR1-KD clone DshR 97 formed significantly larger mammospheres compared to the two control vector clones. P-value
*=0.01-0.05, **<0.01, ****<0.0001.
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Figure 2.10: DEAR1 knockout in DCIS.COM cells also generates larger primary
mammospheres. A) DCIS cells were plated at a density of 500 cells/well in low-attachment
mammosphere conditions. Similar to the DEAR1-KD DCIS clone, knockout of DEAR1 by
CRISPR technology does not consistently result in an increase in primary mammosphere
number. B) Three of six DEAR1-KO clones consistently generate significantly larger
mammospheres compared to DEAR1-expressing DCIS clones and all DEAR1-KO clones form
multiple mammospheres larger than 150μM. P-value ***<0.001, ****<0.0001.
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Figure

2.11:

All

DCIS.COM

mammospheres

formed

secondary

and

tertiary

mammospheres, but DEAR1-KO clones consistently formed larger mammospheres with
each passage. A) DCIS clones demonstrate differences in self-renewal capacities. Both control
and DEAR1-KO clones are capable of generating secondary and tertiary mammospheres. B)
DEAR1-KO clones continue to generate larger mammospheres after the second and third
passages. The consistent increase in mammosphere size in DCIS cells with reduced or no
DEAR1 expression indicates that loss of DEAR1 could regulate progenitor cell proliferation.
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93.53uM±32.37,

p=0.23)

although

DEAR1-KO

clones continued to generate

larger

mammospheres in the DMSO and TGF-β inhibitor cohorts (KO 167.36uM±70.44 vs WT
95.29uM±30.83, p<0.0001 and KO 167.3uM±67.39 vs WT 125.19uM±56.05, p<0.01,
respectively; Figure 2.12B). Overall this data suggests that loss of DEAR1 expression regulates
progenitor cell properties as demonstrated by generation of larger mammospheres by DEAR1KO clones that is not regulated through the TGF-β pathway.

2.3

Discussion
Since loss of DEAR1 resulted in an EMT signature and increased migration in the

presence of TGF-β in HMECs, I hypothesized that loss of DEAR1 would also allow cells to
acquire stem/progenitor cell properties. Stable DEAR1 KD in HMECs resulted in significantly
greater number of mammospheres and exposing DEAR1-KD HMECs to TGF-β1 enhanced the
mammosphere phenotype. These results confirm results of experiments performed in HMECs
that DEAR1 prevents mammosphere formation independently of its function in regulating the
canonical TGF-β pathway. Further evidence of this theory was provided when I tested whether
the mammosphere phenotype is dependent on SMAD3. Utilizing DEAR1-SMAD3 double KD
HMECs, I observed that non-treated double KD cells did not form significantly fewer
mammospheres compared to DEAR1 KD alone, but that TGF-β1 treated DEAR1-SMAD3 double
KD cells formed approximately half the number of primary mammospheres compared to DEAR1
KD alone. This data suggest that the mammosphere phenotype is only partially dependent on
SMAD3 in the context of TGF-β signaling, and provide further evidence that mammosphere
formation may be dependent on DEAR1 independently of TGF-β-mediated EMT. There are
several known pathways that have been demonstrated to play roles in the regulation of
stemness, such as the Hippo, Wnt, Notch, and MAP kinase pathways [15, 64, 69, 81]. It is
possible that DEAR1 may regulate one of these alternative pathways to regulate stem/progenitor
cell properties. It was also shown that overexpression of TWIST, a known EMT regulator, in
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Figure 2.12: TGF-β inhibits formation of DCIS mammospheres. TGF-β treatment results in
reduced mammosphere quantity in DCIS.COM cells, however DEAR1-KO DCIS.COM clones
treated with TGF-β formed significantly more primary mammospheres compared to treated
control clones. A) DCIS.COM clones pre-treated with TGF-β and maintained in mammosphere
growing conditions supplemented with TGF-β formed significantly fewer mammospheres
compared to untreated cells (p<0.0001). However, DCIS-KO DCIS clones formed significantly
more primary mammospheres compared to treated DC12 control clone (p<0.0001). Treatment
with TGF-β and TGF-β inhibitor rescued the phenotype. B) Although DMSO-treated DEAR1-KO
DCIS clones still formed larger mammospheres compared to DMSO-treated control clones, TGFβ-treated DEAR1-KO DCIS clones failed to generate larger mammospheres compared to control
clones.
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human mammary epithelial cells can confer stemness independently of EMT [84, 85]. Thus, it is
possible that DEAR1, a regulator of EMT, can affect stem/progenitor cell properties without
initiation of an EMT program.
Although self-renewal studies revealed that loss of DEAR1 does not confer self-renewal
capacity, this does not eliminate the possibility that DEAR1 may regulate progenitor cell
properties. I identified a small population of bipotent cells within primary mammospheres that coexpress CK8/18, a luminal specific surface marker, and CK5, a basal/myoepithelial specific
surface marker. This was also demonstrated by Mani and colleagues using CK14 and CK8/18
antibodies on HMLE mammospheres [57]. Wang et al. demonstrated that BT474, MDA-MB-361,
and MCF7 breast cancer cell lines expressed CK5 when grown as mammospheres but not in 2D
culture [120]. Primary mammospheres also stained highly for ALDH1, indicating that cells grown
in mammosphere conditions are enriched for stem and/or progenitor cell properties, as ALDH1
has been demonstrated as a marker of both stem and progenitor cells in a variety of cell types
and is associated with migration and invasion [77, 79, 80]. Loss of DEAR1 also resulted in a
slight increase in the population of basal progenitor cells (EpCAM-/CD49f+) in 2 of 3 DEAR1-KD
HMEC clones. In a study by Proia and colleagues, mutations in the tumor suppressor and breast
cancer susceptibility gene, BRCA1, resulted in a significant increase in the proportion of
EpCAM−/CD49f+ cells, suggesting that mutation of BRCA1 leads to altered progenitor cell fate,
mainly through increased population of basal progenitor cells [88]. Other studies have shown
that BRCA1 mutations or deficiency results in increased incidence of basal-like tumors and
induction of the EMT program through activation of TWIST [112, 121, 122]. Furthermore, in a
FACS analysis using CD44 and CD24 surface markers, loss of DEAR1 in two DEAR1-KD clones
resulted in decreased CD24 expression leading to an increase in the CD44:CD24 ratio. CD24
expression is associated with the luminal epithelial cell phenotype and its loss of expression has
been observed in metastatic breast cancer cells [77, 80, 123]. Although we did not see an
increase in CD44 expression in DEAR1-KD HMECs, it is important to note that utilizing surface
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markers to identify stem and progenitor cell populations is context-dependent and marker
combinations vary between different cell types and cell lines. In a study by Smart and colleagues,
using CD49f and CD24 provided better stratification than CD44 and CD24 [124]. As a whole,
these results indicate that although DEAR1 may not affect self-renewal, it may still function as a
regulator of progenitor cell properties and that loss of DEAR1 increases the number of progenitor
cells capable of forming mammospheres. It is also interesting that loss of DEAR1 in HMECs
causes a shift in the population of differentiated basal/basal progenitor cells since our previous
study in a cohort of young female breast cancer patients revealed that loss of DEAR1 significantly
correlated with triple negative breast cancer, which contains a subset of basal-like cancers that
is associated with an EMT signature [6, 100].
To study the effects of DEAR1 on stem/progenitor cell properties, I utilized a DCIS cell
line, MCF10DCIS.COM, that demonstrates mammosphere forming capabilities [15, 81] and
expresses wildtype DEAR1. Loss of DEAR1 expression, through either lentiviral shRNA KD or
CRISPR-mediated knockout, in DCIS.COM cells did not result in consistent changes in primary
mammosphere quantity, but rather a significant increase in mammosphere size compared to
respective control cells, even after several passages. The difference in mammosphere
phenotype between DCIS cells and HMECs could be due to difference in cell lines and inherent
differences between genomes (one being a stage 0 breast cancer cell line and the other an
immortalized human mammary epithelial cell line). This data is consistent with what has been
established regarding mammosphere quantity and size. While the number of mammospheres is
an indication of self-renewal capacity, the size of mammospheres infers a larger population of
proliferative progenitor cells [112]. This data provides further evidence that DEAR1 regulates
progenitor cell properties in HMECs and DCIS cells.
Another phenotype that differed between DEAR1 loss in DCIS cells and HMECs was the
effect of TGF-β on mammosphere formation. Interestingly, exposure to TGF-β caused an
opposite effect on mammosphere formation in DCIS cells compared to HMECs in that the number
of mammospheres was significantly reduced in both DEAR1-WT and DEAR1-KO DCIS clones,
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although the number of mammospheres formed in DEAR1-KO clones was higher than those of
DEAR1-WT clones. A possible explanation for this phenomenon could be due to the tumor
suppressive role of TGF-β that is highly context-dependent. A study by Wang and colleagues
demonstrated that TGF-β pre-treatment in BT474 and MDA-MB-361 cell lines resulted in higher
MFEs, but pre-treatment in MCF7 cells resulted in decreased MFE compared to untreated
controls [120]. Several studies have demonstrated that TGF-β inhibits proliferation in multiple cell
types, including cancer cell lines, in part through its regulation of p15INK4B, p21, and c-Myc [39].
It is now clear that TGF-β acts as a tumor suppressor in normal development and in the earlier
stages of cancer, but switches to an oncogenic role in late stage cancer and facilitates metastasis
through its involvement in inducing EMT [30, 39, 43]. Since 76N-E6 cells were immortalized by
HPV E6, the inactivation of p53 may have also protected these HMECs from TGF-β’s growth
inhibition [46].
Together, this data provides evidence that loss of DEAR1 in HMECs and DCIS confers
progenitor cell properties that is independent of TGF-β-mediated EMT. Further experiments
could be designed to understand the specific impacts of DEAR1 loss on progenitor cell fate and
elucidate the effects of DEAR1 on differentiation capabilities in vivo.
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CHAPTER 3: Defining the mechanism by which DEAR1 mediates stem and/or progenitor
cell properties
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3.1

Introduction
Several known oncogenic pathways have been implicated in mediating stemness in

mammary epithelial cells and the formation of mammospheres in vitro, including Notch, Hippo,
MAPK/Akt, and TGF-β signaling pathways [15, 57, 81, 114, 125]. Transcription factors that
mediate the EMT program have been demonstrated to also play roles in self-renewal,
differentiation, and determining cell fate [57]. It is unknown whether expression of these factors
is the cause or a consequence of acquiring stem cell properties, though some studies have
demonstrated that overexpression of specific transcription factors results in an increased
population of stem and/or progenitor cells.
In particular, overexpression of TWIST1, ZEB1, FOXC2, and SNAI1/2 proteins in human
mammary epithelial cells was shown to generate cells with stem-like phenotypes, including
CD44+/CD24- marker profile and mammosphere formation [126, 127]. TWIST1 overexpression
resulted in reduction of CD24 epithelial differentiation marker and expression of BMI1, a stem
cell factor involved in self-renewal [84, 128]. ZEB1 expression has been found to correlate with
poorly differentiated pancreatic, breast, and colorectal tumors [56, 129, 130]. Repression of ZEB1
in pancreatic cancer cell lines resulted in reduced CD24+/CD44+ pancreatic stem cell population,
failure to form tumorspheres, tumor-initiating capacity assayed by in vivo limited dilution assay,
and inhibition of stem cell factors including BMI1 and SOX2 [129]. Furthermore, KD of ZEB1
expression in metastatic breast cancer cells resulted in repression of epithelial markers MUC1
and CD24 [130]. FOXC2, another prominent EMT regulator, was highly expressed in the
CD44+/CD24- stem cell population and ectopic expression resulted in HMLER cells gaining stem
cell properties including increased mammosphere formation and a significant shift from CD44/CD24+ surface marker expression to CD44+/CD24- phenotype. Additionally, FOXC2 induces
expression of genes that are enriched in basal tumors [127]. SNAI1 negatively regulates miR34, which inhibits stemness and promotes cell differentiation [126]. SNAI2 was shown to
cooperate with SOX9 in murine mammary luminal epithelial cells to drive cells into a more dedifferentiated state [87]. SNAI2 KD in HMECs led to high expression of luminal markers, including
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EpCAM, E-cadherin, MUC1, and CD24, implying that SNAI2 is a repressor of luminal
differentiation [72]. Overexpression of SNAI2 in MCF10A cells resulted in an increase in the
CD44+/CD24- population and acquired mammosphere-forming capabilities; this observation was
not replicated in the MCF-7 luminal breast carcinoma cell line, suggesting that SNAI2-mediated
acquisition of stem-like properties is context-dependent [72, 86]. Furthermore, SNAI2
overexpression was observed in breast carcinomas of the basal subtype, often associated with
BRCA1 mutation, and demonstrated high expression of stem cell factors CD133 and BMI1 [88,
131].
We have preliminary data showing that TGF-β exposure and loss of DEAR1 in 76N-E6
HMECs resulted in a significant increase in SNAI2 and ZEB2 mRNA levels. Since we observed
a mammosphere phenotype with loss of DEAR1 in the absence of TGF-β signaling in HMECs,
we hypothesize that these EMT-related transcription factors are upregulated in the context of
DEAR1 downregulation and are, in part, responsible for the mammosphere phenotype.

3.2

Results
Utilizing 76N-E6 HMECs, control and DEAR1-KD clones were grown in 2D culture in the

absence and presence of TGF-β for qRT-PCR analysis. Results indicate that loss of DEAR1 led
to a significant increase in basal SNAI2 and ZEB2 mRNA compared to untreated control cells
(1.44 fold change, p=0.0002 and 13.28 fold change, p<0.0001, respectively) and that this is
enhanced when cells were grown in the presence of TGF-β (3.11 and 76.56 average fold change,
respectively, p<0.0001, Figure 3.1A&B), confirming our previous observations. Since miR-200
family members negatively regulate ZEB proteins, I evaluated expression levels of miR-200b and
miR-200c to determine if loss of DEAR1 affected these miRNAs known to inhibit ZEB2. qRTPCR results show that miR-200b levels decrease in DEAR1-KD cells after TGF-β exposure, but
not significantly different compared to the basal level of expression in the untreated control vector
cells (1.2 fold change, p=0.89, Figure 3.1C) while miR-200c levels steadily increased after
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Figure 3.1: Loss of DEAR1 in HMECs results in increased basal expression of SNAI2 and
ZEB2 mRNA. A) Basal SNAI1 mRNA expression in a DEAR1-KD clone is significantly higher
compared to a control vector clone. SNAI2 levels increase after TGF-β treatment in both CshR
and DshR clones, however the increase in DshR clone remains significantly greater than the
treated CshR clone. B) Basal ZEB2 mRNA expression in the DEAR1-KD clone is significantly
higher compared to control and, similar to SNAI2 levels, also increase after treatment with TGFβ that is significantly greater compared to treated control. C-D) miR-200b and miR-200c, negative
regulators of ZEB1, expressions are significantly higher at basal level in DEAR1-KD clone
compared to control vector, indicating that loss of DEAR1 affects ZEB1 mRNA expression
independently of miRNA regulation. P-value **<0.01, ***<0.001, ****<0.0001.
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TGF-β exposure (1.89 fold change, p<0.0001, Figure 3.1D). At basal level, in which cells are not
exposed to TGF-β, DEAR1-KD cells express higher levels of miR-200b (1.45 fold change,
p=0.01) and miR-200c (1.67 fold change, p=0.003) compared to untreated control cells,
indicating that loss of DEAR1 mediates overexpression of ZEB2 independently of miR-200 family
expression.
Next I performed qRT-PCR using two control vector clones and three DEAR-KD clones
to evaluate basal expression of SNAI2, ZEB1, and ZEB2 mRNA. As shown in Figure 3.2A, all 3
DEAR1-KD clones exhibited significantly higher expression of SNAI2 and ZEB1 mRNA (for pvalues please refer to table listed in Figure 3.2A). Further assays using untreated and TGF-βtreated HMECs confirmed that loss of DEAR1 resulted in basal upregulation of SNAI2, ZEB1,
and ZEB2 baseline mRNA and that exposure to TGF-β increased these mRNA levels in different
clones at various times after exposure (Figure 3.2B – D). Since I observed increased primary
mammospheres with DEAR1-KD alone even in the context of SMAD3 downregulation, I asked
whether these same transcription factors are affected in DEAR1-SMAD3 double KD cells. qRTPCR results indicate that SNAI2 baseline expression in DEAR1-KD and DEAR1-SMAD3 double
KD cells remained significantly upregulated (1.93 fold change, p=0.0001; 1.42 fold change,
p=0.002, respectively) compared to the control vector cell line (Figure 3.2E). This demonstrates
that SNAI2 expression is not dependent on TGF-β-SMAD3 signaling and that loss of DEAR1
alone can confer upregulation of SNAI2 mRNA level. Since SNAI2 mRNA was not affected by
loss of SMAD3 and has been shown to be involved in driving basal cell lineage and
mammosphere formation [86, 88], it became a potential candidate gene mediating stemness in
the context of DEAR1 downregulation.
To test if DEAR1 regulates SNAI2 expression at the transcriptional level, HEK293T cells
were co-transfected with pGL3-SNAI2 luciferase vector that contains the SNAI2 promoter region
upstream of the luciferase gene and pcDNA-DEAR1 or pcDNA-CNTL. Results consistently show
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Figure 3.2: SNAI2, ZEB1, and ZEB2 basal mRNA levels are significantly higher in DEAR1KD clones and SNAI2 mRNA expression remains increased in DEAR-SMAD3 double KD
cells. A) Baseline expressions of SNAI2 and ZEB1, and ZEB2 mRNA are significantly higher in
all three DEAR1-KD clones compared to control vectors. Table below panel A summarizes fold
changes across all three clones and corresponding p-values. B-D) ZEB1, ZEB2, and SNAI2
mRNA levels across two control vector clones and three DEAR1-KD clones. In this analysis, all
three DEAR1-KD clones exhibit significantly higher basal levels of ZEB1, ZEB2, and SNAI2
mRNA compared to control vectors and treatment with TGF-β results in an increase of mRNA
levels at various time points in different clones. E) Analysis of DEAR1-SMAD3 double KD cells
reveals that SNAI2 mRNA expression remains significantly higher compared to control cells,
suggesting that SNAI2 expression could be independent from SMAD3 expression in the absence
of TGF-β signaling. P-value *=0.1-0,5, **<0.01, ***<0.001, ****<0.0001.
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that increasing concentrations of DEAR1 (200, 300, and 400ng) repressed luciferase activity
compared to control cells at both 24 hours post-transfection (0.64, 0.58, and 0.40 fold change,
respectively; p<0.001 vs pcDNA, Figure 3.3A) and 48 hours post-transfection (0.48, 0.34, and
0.24 fold change, respectively; p<0.001 vs pcDNA, Figure 3.3B). To test if DEAR1 may also
regulate SNAI2 at the protein level, control and DEAR1-KD HMECs were used for western blot
analysis. Results indicate that SNAI2 basal protein level was increased in all three DEAR1-KD
clones and that this upregulation was enhanced in the presence of TGF-β (Figure 3.4A). To test
if DEAR1 associates with SNAI2, HEK293T cells were co-transfected with HA-DEAR and MycSNAI2 vectors for co-immunoprecipitation assays. Results reveal that DEAR1 associates with
SNAI2 (Figure 3.4B). Furthermore, a ubiquitination assay in HEK293T cells indicate that ectopic
expression of DEAR1 promotes polyubiquitination of SNAI2 (Figure 3.4C). To test if a point
mutation, C11A, in the RING domain that has been shown by others to be a loss-of-function
mutation and utilized in other studies investigating DEAR1’s ligase function [108, 109] has an
effect on DEAR1’s ability to polyubiquitinate SNAI2, I utilized a DEAR1-C11A mutant plasmid
generated by Dr. Balasenthil. The C11A mutation did not affect ubiquitination of SNAI2 (Figure
3.4D) and further studies are required to determine which domains of DEAR1 are crucial for
target binding and ubiquitination. Cumulatively, these results indicate that DEAR1 is a negative
regulator of SNAI2 expression independent of the canonical TGF-β pathway and that SNAI2 is a
good candidate for mediating the stem/progenitor cell properties in HMECs.
To determine if DEAR1-mediated SNAI2 expression affects mammosphere formation, I
used DshR clones to perform lentiviral shRNA KD of SNAI2, generating DEAR1-SNAI2 double
KD pooled HMECs that were used for mammosphere assays. As shown in Figure 3.5, loss of
SNAI2 in either of the DEAR1-KD clones did not significantly reduce the quantity of
mammospheres formed compared to the pooled DEAR1-KD control vector (DshR-cntl), although
there was a significant decrease in the number of mammospheres formed by DshR1-shSNAI2
compared to the parental DshR1 clone (4.5 vs 29.25, p<0.0001). Although the DshR3-shSNAI2
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Figure 3.3: SNAI2 promoter-activated luciferase expression is inhibited by ectopic DEAR1
expression in HEK293T cells. A) Cells co-transfected with pGL3-SNAI2 luciferase vector and
increasing concentrations of pcDNA-DEAR1 demonstrate significant reduction of luciferase
activity. Cells were harvested 24 hours post-transfection. B) The same inhibitory trend is
observed in cells harvested 48 hours post-transfection. P-values ***<0.001, ****<0.0001.
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Figure 3.4: Loss of DEAR1 in HMECs result in increased SNAI2 protein; DEAR1 binds to
and polyubiquitinates SNAI2. Loss of DEAR1 in HMECs results in an increase in baseline
SNAI2 protein expression and is further enhanced in the presence of TGF-β. Co-IP and
ubiquitination assays in HEK293T cells reveal that DEAR1 and SNAI2 interact to promote SNAI2
polyubiquitination. A) Western blot analysis of SNAI2 expression show that SNAI2 protein
increases in all untreated DEAR1-KD HMEC clones compared to untreated control HMECs.
Treatment with TGF-β enhances SNAI2 expression in all clones. B) Co-IP using HEK293T cells
co-transfected with HA-DEAR1 and Myc-SNAI2 vectors reveal that DEAR1 and SNAI2 interact.
Cell lysates were pulled down using anti-HA antibody and western blot analysis using anti-Myc
antibody shows a band corresponding to SNAI2 only in cells transfected with DEAR1 and SNAI2.
C) HEK293T cells were transfected with pcDNA-DEAR1, Myc-SNAI2, and 8x-HA-ubiquitin. Cell
lysates were harvest 48 hours post-transfection and pulled down with anti-Myc antibody. Western
blot analysis using anti-HA antibody shows that SNAI2 is polyubiquitinated only in the presence
of DEAR1. D) The ubiquitination assay was repeated using a RING domain mutant, DR1-C11A,
to determine if the interaction and polyubiquitination is dependent on DEAR1 RING-finger domain
function. Western blot analysis shows that DR1-C11A still interacts and polyubiquitinates SNAI2,
suggesting that the interaction between DEAR1 and SNAI2 may be indirect.
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Figure 3.5: SNAI2 knockdown in DEAR1-KD HMECs did not fully rescue mammosphere
phenotype. Using two DEAR1-KD clones, stable SNAI2 KD was achieved by lentiviral GFPshRNA vectors. Western blot analysis confirmed SNAI2 downregulation after two rounds of GFP
sorting. Control vectors, parental DshR clones, DshR control pool, and DshR shSNAI2 pooled
cells were grown in mammosphere conditions. Overall, there were no significant differences
between DshR-cntl and DshR shSNAI2 mammospheres, although there is a decreasing trend in
DshR shSNAI2 mammospheres. P-values ****<0.0001.
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pooled cells formed fewer primary mammospheres compared to DshR-cntl pooled cells, this
difference was not significant (4.75 vs 9.5, p=0.17). This data suggests that loss of SNAI2 is not
sufficient to completely rescue the mammosphere phenotype and that other factors may be
involved in regulating the stem cell phenotype in HMECs.

3.3

Discussion
Using qRT-PCR, I confirmed initial experiments demonstrating that exposure to TGF-β

signaling in the context of DEAR downregulation led to an increase in SNAI2 and ZEB2 mRNA.
Results also showed that basal levels of SNAI2 and ZEB2 were significantly higher in DEAR1KD clones, compared to control vector cells, indicating that loss of DEAR1 alone was sufficient
to cause an upregulation of mRNA levels of EMT regulators. In regards to ZEB2 mRNA
expression, I eliminated the possibility that its negative regulators miR-200b and miR-200c
affected ZEB2 mRNA at baseline levels. Analysis of EMT regulators in two control vector and
three DEAR1-KD HMEC clones using qRT-PCR revealed that loss of DEAR1 demonstrated
upregulation of SNAI2, ZEB1 and ZEB2 mRNA in the absence TGF-β signaling. Importantly,
SNAI2 mRNA expression was not significantly affected in DEAR1-SMAD3 double KD cells,
indicating that SNAI2 may be an EMT-related/stemness factor that mediates the mammosphere
phenotype in DEAR1-KD clones independently of the TGF-β-SMAD3 axis [86, 87, 121].
Luciferase assays indicated that ectopic expression of DEAR1 inhibits expression of
luciferase driven by the SNAI2 promoter, demonstrating that DEAR1 transcriptionally inhibits
SNAI2 expression, though whether this is a direct or indirect mechanism requires further
investigation. This data corroborates with the discovery from Liu et al. that DEAR1 indirectly
negatively regulates SNAI2 by regulating c-Jun in cervical cancer cells, although the precise
mechanism of c-Jun inhibition by DEAR1 was not described [107]. Other studies have identified
regulatory pathways that affect SNAI2 at the transcriptional level, including SPARC/Akt in
melanoma cells, NF-κB pathway activation in breast cancer cells, and ER-mediated MTA3
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activation which complexes with the transcriptional corepressor unit, Mi-2/NuRD, in mammary
epithelial cells [132-135]. Unpublished data by Dr. Balasenthil in our lab suggests that DEAR1
plays a role in mediating ER stabilization, thus serving as a potential pathway by which DEAR1
affects SNAI2 transcriptional activation. A study by Ye et al. identified another mechanism by
which ERα mediates SNAI2 transcriptional repression through recruitment of histone
deacetylase 1 (HDAC1) through nuclear receptor co-repressor 1 (NCOR1) binding to the
estrogen-response element sequences found in the SNAI2 promoter [136]. It would be interesting
to evaluate if DEAR1 participates in any of these pathways that transcriptionally mediate SNAI2
expression. In addition to increased SNAI2 mRNA, I also observed an increase in SNAI2 protein
in DEAR1-KD HMEC clones in the absence of TGF-β signaling. Co-IP and ubiquitination assays
indicate that DEAR1 binds to SNAI2 and promotes its polyubiquitination, although data suggests
that this mechanism of SNAI2 regulation by DEAR1 may be indirect since there is still
polyubiquitination of SNAI2 by the DEAR1 C11A RING domain mutant. Alternatively, a single
point mutation may not be sufficient to abrogate DEAR1’s ability to polyubiquitinate its target
proteins; more studies using deletion constructs will provide insight in regards to which domain(s)
is/are crucial for target recognition and ubiquitination. DEAR1 may act through other posttranslational regulators of SNAI2, such as BRCA1, p53/MDM2, or Wnt/GSK3β and β-Trcp1 E3
ubiquitin ligase [52, 88, 137]. Unpublished data by Dr. Balasenthil suggests that DEAR1 binds to
and stabilizes p53, which regulates SNAI2 polyubiquitination by MDM2 and consequential
proteasomal degradation [52].
To test if DEAR1-mediated regulation of SNAI2 affects mammosphere formation, SNAI2
expression was knocked down in DEAR1-KD HMECs. Using the DshR1 cells, I showed that
although there is a slight reduction, there is no significant difference in mammosphere quantity
between DshR1 control and DshR1 shSNAI2 pooled cells. However, there a significant reduction
of mammospheres between parental DshR1 and DshR1 shSNAI2 cells. It is possible that the
shRNA control vector is causing an unknown off-target effect that may affect mammosphere
formation in this particular clone. DshR3 clone did not generate significantly more
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mammospheres compared to the control vector clone, which was demonstrated multiple times
in other experiments (refer to Chapter 2, Figures 2.3 and 2.4). The DshR3 control pooled cells
generated more mammospheres compared to CshR1 and CshR2 control vector cells. Although
I observed a reduction of mammospheres formed by DshR3 shSNAI2 pooled cells, this is not a
significant difference when compared to DshR3 control pooled cells, potentially due to high error
bars and a larger sample size is needed for a more accurate statistical analysis. Alternatively,
using pooled cells may not be an accurate representation of effects of loss of SNAI2 in the context
of DEAR1 downregulation. Another possibility is that loss of SNAI2 in both DEAR1-KD clones is
not sufficient to reverse the mammosphere phenotype and that SNAI2 is an indirect mediator,
contrary to what has been previously published.
For the first time, I demonstrate a novel mechanism of SNAI2 regulation at the
transcriptional and post-translational level through the tumor suppressor, DEAR1, which is
independent of the TGF-β-SMAD3 signaling axis. More work is required to better understand the
relationship between DEAR1, SNAI2, and the effects of this regulatory mechanism on
stem/progenitor cell properties, in particular the role of SNAI2 on progenitor cell fate and basal
cell lineage in the context of DEAR1 regulation and breast carcinogenesis.
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CHAPTER 4: Loss of DEAR1 correlates with poor overall survival in invasive breast
cancer and time to metastasis in triple negative breast cancer
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4.1

Introduction
It was previously demonstrated that DEAR1 protein expression in a cohort of young

females between the ages of 25 and 49 years of age diagnosed with invasive breast carcinoma
correlates significantly with local recurrence-free survival after a 15-year follow-up (p=0.0334)
and associates with PR negative status (p=0.0321), triple negative breast cancer subtype
(p=0.0362), and strong family history (p=0.0139) [100]. In a Korean cohort of 70 TNBC patients,
DEAR1 was listed as one of the most frequently mutated genes with a frequency of 9%. One
somatic variant, c.1094T>G, occurred in 6% of cases and was predicted to be deleterious based
on SIFT and PolyPhen2 scores [138]. Studies by Quintás-Cardama et al. observed that loss of
DEAR1 expression correlates with poor overall survival (p=0.00038) and shorter survival
(p=0.00004) in AML patients. They also observed significant alterations in stem cell regulatory
pathways, including Wnt/β-catenin and Notch signaling [106]. These studies indicate the
importance of utilizing DEAR1 expression to evaluate prognosis and risk of early-onset TNBC,
which has the worst prognosis compared to other breast cancer subtypes [10, 139, 140].
Expression of EMT regulators, including SNAI1/2, TWIST1, and ZEB1, was shown to be
deregulated in breast cancer and correlated with poor prognosis, tumor recurrence, and
increased aggressiveness [34, 47, 141]. Importantly, the EMT-gene signature is frequent in
basal-like tumors, a subgroup of the TNBC subtype that is associated with a poorly differentiated
phenotype [141]. High expression and/or amplification of SNAI2 were observed in multiple
epithelial cancers, including prostate, lung, and breast carcinomas [1, 142]. SNAI2 is an
established transcriptional repressor and mediator of EMT, notably through inhibiting expression
of E-cadherin, occludin, claudin, and integrins, and its expression in breast carcinoma correlates
with a de-differentiated phenotype and poor prognosis [47]. Furthermore, SNAI2 overexpression
was significantly associated with high tumor grade, recurrence, and metastasis in primary breast
cancer tissues [54]. The association between SNAI2 and a partially differentiated phenotype in
breast carcinoma further provides evidence that SNAI2 could function in regulating epithelial
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differentiation in mammary tissue. Additionally, SNAI2 is upregulated in basal-like breast
carcinomas associated with BRCA1 mutations [88].
Given that loss of DEAR1 results in an enhanced progenitor cell phenotype and correlates
with TNBC and strong family history, upregulation of SNAI2 was shown to associate with the
basal-like subtype of TNBC and regulates differentiation, and the discovery of an inverse
correlation between DEAR1 and SNAI2 in vitro, I asked whether this correlation exists in breast
cancer patients and if I can utilize DEAR1 and SNAI2 expression to determine clinical outcome.

4.2

Results
Utilizing cBioPortal to analyze gene expression profiles across multiple cancer datasets,

I observed DEAR1 loss of heterozygosity and SNAI2 amplification and/or overexpression in
multiple cancer types (Figure 4.1) [1]. Analysis of the METABRIC cohort of invasive breast
carcinomas (n=2509) [1, 140] revealed that DEAR1 LOH and/or loss of expression is observed
in 17% of patients and significantly associates with poor overall survival (OS) (p=0.00002939,
Figure 4.2). In the same cohort, SNAI2 amplification and/or overexpression occurred in 12% of
patients with near significant association with poor OS (p=0.0562, Figure 4.3). DEAR1
LOH/downregulation and SNAI2 amplification/overexpression has a significant tendency to cooccur in this dataset (p<0.001) and alterations in both genes associate with poor OS at higher
significance compared to DEAR1 alterations alone (p=0.00002067, Figure 4.4).
Using the breast cancer Gene-Expression Miner (bc-GenExMiner) v4.1 online genomic
data mining tool [143, 144], I examined DEAR1 and SNAI2 mRNA in TNBC and non-TNBC
samples across multiple published annotated and genomic data since DEAR1 and SNAI2
expressions have demonstrated associations with the TNBC subtype. Results indicate that
DEAR1 expression is significantly reduced in basal-like and TNBC samples compared to other
breast cancer subtypes (p<0.0001, Figure 4.5A – C). Furthermore, SNAI2 expression is
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Figure 4.1: DEAR1 LOH and SNAI2 alterations are frequent in multiple cancer types in
cBioPortal. A) DEAR1 LOH is observed in a variety of epithelial cancers, including breast,
ovarian, bladder, and pancreatic carcinomas. B) Amplification is the most commonly observed
alteration of SNAI2 in multiple cancer types, including breast, bladder, skin, and pancreatic
cancers. Other cancers, such as non-small cell lung and esophagogastric cancers, also harbor
SNAI2 mutations.
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Figure 4.2: DEAR1 LOH and mRNA downregulation occurs in 17% of invasive breast
carcinoma patients in the METABRIC cohort (n=2,509). A) Of the 2,491 sequenced samples,
DEAR1 undergoes LOH and/or mRNA downregulation in 415 cases. B) Overall survival for cases
with and without DEAR1 alterations. DEAR1 LOH/downregulation correlates significantly with
poor overall survival with median survival of 122.8 months compared to 168.3 months in the
unaltered cohort (p=0.00002939).
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Figure 4.3: SNAI2 amplification and mRNA upregulation occurs in 12% of invasive breast
carcinoma patients in the METABRIC cohort (n=2,509). A) Of the 2,491 sequenced samples,
SNAI2 undergoes amplification and/or mRNA overexpression in 303 cases. B) Overall survival
for cases with and without SNAI2 alterations. SNAI2 amplification/upregulation shoes a trend but
does not correlate significantly with poor overall survival (p=0.0562).
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Figure 4.4: Alterations in both DEAR1 and SNAI2 serve as a more significant predictor of
overall survival in the METABRIC cohort (n=2,509). A) DEAR1 LOH/mRNA downregulation
and SNAI2 amplification/overexpression alterations have a significant tendency to co-occur
(p<0.001). B) Alterations in both DEAR1 and SNAI2 associate with poor OS even more
significantly compared to DEAR1 alterations alone (p=0.00002067).
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Figure 4.5: DEAR1 and SNAI2 mRNA expressions are altered in basal-like and triple
negative breast cancer. A-C) DEAR1 mRNA level is significantly downregulated in the basallike and TNBC subtypes compared to other breast cancer subtypes (p<0.0001). D) SNAI2 mRNA
expression is significantly upregulated in TNBC compared to non-TNBC subtype (p=0.0001). E)
There is a significant inverse correlation between DEAR1 and SNAI2 mRNA expression; on
average, SNAI2 expression is higher in samples where DEAR1 expression is below the median
(p<0.0001).
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significantly upregulated in cancers of the TNBC subtype compared to the non-TNBC group
(p=0.0001, Figure 4.5D). I also observed an inverse correlation between DEAR1 and SNAI2
expression in breast cancer samples (p<0.0001, Figure 4.5E).
Since there is an evident correlation between DEAR1 expression and TNBC/basal-like
phenotype, I analyzed DEAR1 expression in a TNBC tissue microarray (TMA) that consisted of
153 breast cancer samples, 103 of which are TNBC. The majority of patients in this cohort were
Caucasian (65%), HER2 negative (98%) and diagnosed at an early stage. Details are
summarized in Figure 4.6. Statistical analysis to correlate DEAR1 expression with clinical status
and outcomes was performed using all TMA samples (n=153) and in TNBC-only cases (n=103).
Results indicate that DEAR1 expression, when dichotomized by the median or distributed into
tertiles, is significantly associated with age of diagnosis only in TNBC in which loss of DEAR1
correlated with a younger age of diagnosis (p=0.04 and p=0.01, respectively, Figure 4.7A).
When age was dichotomized into ‘younger than 50 years of age’ and ’50 years or older’, loss of
DEAR1 significantly associated with patients younger than 50 years of age (p=0.03, Figure
4.7B). There was also a statistically significant correlation between DEAR1 protein expression
and time to metastasis in TNBC cases when DEAR1 expression was dichotomized by the median
(HR=0.41, 95% CI: 0.17-1.03, p=0.05, Figure 4.7C). Collectively, this data indicates the
importance of DEAR1 expression in IDC, specifically in TNBC. With further investigations, we
hope to utilize DEAR1 and SNAI2 expression to predict patient outcomes and stratify patients for
stringent follow-up and treatment.

4.3

Discussion
At the genomic level, we observed frequent DEAR1 LOH, a common genetic event in

cancer that could potentially unmask somatic mutations in tumor suppressor genes when the
wildtype allele is lost, and SNAI2 upregulation in the METABRIC invasive breast carcinoma
cohort (n=2509). While DEAR1 LOH and/or mRNA downregulation, but not SNAI2 alterations,
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Table 4.1: Patient demographics and tumor characteristics of TNBC TMA. DEAR1 protein
expression in the membrane and cytoplasm was analyzed on a TMA TNBC cohort with Aperio
Technologies. Statistical analysis was performed to determine if there was an association
between DEAR1 expression and clinical status and outcomes, including tumor size, age, race,
and stage.
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A
p=0.01

Age

p=0.04

B

C

DEAR1 H-Score

p=0.03

HR=0.41
95% CI: 0.17-1.03

Figure 4.7: Loss of DEAR1 protein expression significantly correlates with younger age at
diagnosis and shorter time to metastasis in TNBC patients. A) Distribution of age at
diagnosis in TNBC patients by DEAR1 expression dichotomized by the median or categorized
by tertiles of distribution. B) Distribution of DEAR1 expression by age at diagnosis dichotomized
at 50 years of age in TNBC patients. C) Kaplan Meier curve for time to metastasis by DEAR1
expression dichotomized by the median in TNBC patients.
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significantly correlates with poor OS, DEAR1 LOH/downregulation in addition to SNAI2
amplification/overexpression associates with poor OS at greater significance than DEAR1
alterations alone. These results indicate that DEAR1 and SNAI2 expression levels are good
predictors of overall survival in invasive breast cancer patients. Since I observed a correlation
between DEAR1 and SNAI2 expression with respect to a stem/progenitor cell phenotype, it would
be meaningful to study if we can utilize their expression to predict chemotherapy response, risk
of progression from DCIS to IDC, or stratify patients for therapies that target DEAR1-mediated
pathways, such as EMT and SNAI2.
The in vitro data collected thus far indicates that DEAR1 plays a role in regulating
stem/progenitor cell properties, potentially through mediating SNAI2 expression. The EMT and
stem cell phenotype and SNAI2 overexpression have been related to the basal-like subgroup of
the TNBC subtype of breast carcinomas, which exhibit aggressive behavior, poor prognosis, and
high risk of metastasis compared to other breast cancer subtypes. Given that DEAR1 protein
expression in a cohort of young female patients (under 50 years of age) with invasive breast
carcinoma associated significantly with TNBC and strong family history, I evaluated DEAR1 and
SNAI2 mRNA expression in TNBC samples using published annotated genomic data collected
online from the bc-GenExMiner v4.1 tool. DEAR1 mRNA expression demonstrated an inverse
correlation with SNAI2 mRNA expression in basal-like cancer and TNBC; DEAR1 was found to
be downregulated in basal-like and TNBC compared to other luminal A, luminal B, HER2positive, and normal-like breast carcinomas. This provides further evidence that supports the in
vitro observations demonstrating DEAR1’s role in mediating progenitor cell properties and
overexpression of SNAI2 with loss of DEAR1 in HMECs. I further demonstrate that
downregulation of DEAR1 protein expression significantly correlated with early age of onset in
the TNBC TMA, which supports previous data that showed loss of DEAR1 expression associates
with a strong family history of invasive breast carcinoma. Furthermore, loss of DEAR1 protein
expression, when dichotomized by the median, revealed a significant association with shorter
time to metastasis in TNBC patients; patients with DEAR1 expression higher than the median
87

showed a 59% less risk of metastasis compared to patients with DEAR1 expression lower than
the median.
Cumulatively, there is strong evidence demonstrating the importance of DEAR1 copy
number loss and expression, in particular with cases of TNBC, in predicting clinical outcome.
This data indicates that DEAR1, in addition to SNAI2, can be a potential biomarker to determine
prognosis as well as risk of developing early-onset breast cancer and/or metastasis.
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CHAPTER 5: Post-transcriptional regulation of DEAR1 by microRNAs
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5.1

Introduction
MicroRNAs (miRNAs) are short interfering RNA molecules, approximately 21-25 bases

long, which regulate gene expression by binding to target messenger RNA (mRNA) transcripts
at the 3’ untranslated region (UTR) to inhibit translation or promote mRNA degradation by
nucleases. The first miRNA, lin-4, was discovered and characterized in C. elegans in 1993. A
few years later, the second miRNA, let-7, was discovered. Since then, thousands of miRNAs
were identified in several model organisms, including plants, flies, rodents, and primates [145,
146]. In mammals, primary miRNA transcripts are processed in the nucleus by the
Drosha/DCGR8 complex and are exported to the cytoplasm as pre-miRNAs to be further
processed by Dicer RNA III endonuclease. The mature miRNA forms a complex with Argonaute,
a component of the RNA-induced silencing complex (RISC), to mediate target mRNA binding
and regulation [145-147]. While complete complementarity to the target mRNA sequence results
in mRNA degradation, partial complementarity results in translational inhibition. The 5’ end of the
mature miRNA contains the “seed region” that refers to a sequence of 6-8 bases that exhibits
complementary base pairing with the target mRNA sequence located in the 3’UTR. The seed
region is crucial for recognition of target mRNA and is used by target prediction programs to
identify potential targets [146].
MiRNAs function in many cellular pathways including those involved in cell cycle
progression, growth, proliferation, differentiation, and cell death. Approximately 50% of genes
encoding miRNAs are located in fragile regions within chromosomes that are vulnerable to
genomic alterations. De-regulated miRNAs are often observed in many cancer types, including
pancreatic, gastric, lung, and breast cancers [145, 148-150]. Downregulation of tumor
suppressive miRNAs that target oncogenes or upregulation of oncomirs that target tumor
suppressor genes involved in regulating proliferation and invasion can result in tumor formation
and metastasis [145, 146, 150, 151]. For example, the miR-200 family is involved in modulating
epithelial-mesenchymal transition (EMT), which is implicated in promoting invasive properties of
cancer cells, by downregulating expression of the E-cadherin repressors ZEB1/2. In many
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invasive cancers, miR-200 family members are downregulated, allowing for ZEB1/2 activity to
repress E-cadherin expression and promote EMT progression [53, 150]. MiR-21 targets multiple
tumor suppressor genes, including PTEN and Bcl2, and is upregulated in many cancers including
breast cancer, gastric cancer, glioblastoma, pancreatic cancer, and cholangiocarcinoma. MiR221 is another EMT promoter and is upregulated in a number of cancers including glioblastoma,
thyroid cancer, breast cancer, and pancreatic cancer [146, 150-153].
The mechanism by which DEAR1 is downregulated in DCIS and IDC remain unclear;
methylation assays reveal that the DEAR1 promoter is not hypermethylated and in some cell
lines, DEAR1 mRNA is generated although protein expression is not detected. Currently no
miRNAs have been validated to regulate DEAR1 post-transcriptionally. Based on data from
literature and miRNA target prediction programs, miR-10b and miR-196b are of particular
interest. MiR-10b is upregulated in metastatic breast cancer and targets TIAM1, HOXD10, and
RHOC. High levels of miR-10b, induced by EMT initiation and transcription factor Twist, promotes
cell invasion by the suppression of HOXD10 and RHOC [148, 149, 154]. MiR-196b became a
candidate after a screening of miRNAs in pancreatic cancer cell lines in which it was noted that
pancreatic cancer cell lines lacking DEAR1 expression showed high levels of miR-196b. MiR196b overexpression significantly correlates with poor prognosis in gastric cancer [155] and its
overexpression contributes to hematopoietic stem cell maintenance and immortalization of bone
marrow progenitor cells in mixed lineage leukemia [156]. Furthermore, overexpression of both
miR-10b and miR-196b was observed in tumor-associated endothelial progenitor cells that
generate vasculature in high-grade invasive ductal carcinoma [157]. In addition, both candidate
miRNAs are predicted to bind the 3’UTR of DEAR1 based on publically available online miRNA
target prediction tools (Figure 5.1) [158, 159]. Discovery of a miRNA or group of miRNAs that
control DEAR1 levels may lead to a better understanding of DEAR1’s function, explain how
DEAR1 expression is lost in breast cancer, and serve as an avenue for therapeutic interventions.
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Figure 5.1: miR-10b and miR-196b were predicted by at least three prediction algorithms
to target DEAR1. A) An online search tool compares results across five target prediction
algorithms programs. MiR-10b is predicted to target DEAR1 in 4 of 5 programs; miR-196b is
predicted to target DEAR1 in 3 of 5 programs. B) Sequence alignment of DEAR1 3’UTR with
miR-10b and miR-196b. Both miRNAs harbor 7 base complementation with DEAR1 in the critical
5’ miRNA seed region.
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5.2

Results
To determine if miR-10b and miR-196b are valid miRNA candidates that regulate DEAR1

expression, I first analyzed miR-10b and miR-196b expression via qRT-PCR analysis in cell lines
that express or lack DEAR1. 76N-F2V, 76N-E6, and MCF10A immortalized, non-tumorigenic
human mammary epithelial cell lines demonstrate high DEAR1 protein expression whereas
SKBR3, TD474, MCF7, BT20T, H1299, and HCT116 cancer cell lines do not express detectable
DEAR1 protein by western blot analysis (Figure 5.2A). q-PCR results reveal that miR-10b is
overexpressed in 5 of 6 cell lines that lack DEAR1 protein expression compared to DEAR1expressing control cell lines (SKBR3: 4994.43 fold change, p<0.0001; T47D: 576.87 fold change,
p<0.01; BT20T: 13.65 fold change, p<0.01; H1299: 1169.03 fold change, p<0.0001; Hct116:
832.03 fold change, p<0.0001 vs 76N-F2V; Figure 5.2B). Similarly, miR-196b is overexpressed
in 4 of 6 cell lines that lack DEAR1 expression (SKBR3: 13.11 fold change, p<0.0001; T47D:
3.07 fold change, p<0.01; MCF7: 1.95 fold change, p<0.05; Hct116: 4.13 fold change, p<0.01;
Figure 5.2C).
To evaluate if each candidate miRNA has affinity to the predicted binding site in the 3’UTR
of DEAR1 and if binding to this region leads to translational repression, I utilized a pMIRREPORT luciferase expression vector. 60bp oligo strands containing the candidate miRNA
binding region with restriction enzyme sites flanking the 5’ and 3’ ends were designed for ligation
into the multiple cloning site (MCS) at the 3’ end of the luciferase reporter. Oligos contained either
the putative binding site found in the 3’UTR of DEAR1 or the standard binding site in which there
is perfect complementation to a specific miRNA candidate as positive controls. The luciferasefusion plasmid and miRNA mimics were co-transfected into HEK293T cells to determine effects
on luciferase activity. Results demonstrate that both miR-10b and miR-196b significantly inhibit
luciferase activity (p<0.0001, Figure 5.3A&B). Similarly, when the entire DEAR1 3’UTR region
was cloned into the pMIR-REPORT vector, addition of miR-10b and miR-196b mimics resulted
in significant reduction of luciferase activity compared to respective negative controls (p<0.0001,
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Figure 5.2: miR-10b and miR-196b are upregulated in cancer cell lines that lack DEAR1
protein expression. A) Western blot analysis of immortalized, non-tumorigenic human
mammary epithelial control cell lines that express DEAR1 and multiple cancer cell lines that do
not express detectable DEAR1 protein. B-C) Q-PCR analysis of miR-10b and miR-196b
expression in cell lines. Both miRNAs are significantly overexpressed in the majority of cancer
cell lines that lack DEAR1 protein expression. U6 snRNA was used as the internal control for
miRNA qPCR assays. P-value *=0.05-0.01, **<0.01, ****<0.0001.
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Figure 5.3: Expression of miRNA mimics significantly reduces luciferase activity in
HEK293T cells containing putative and standard miRNA binding sites. A) HEK293Ts cotransfected with 25ng pMIR-REPORT luciferase vector containing either putative or standard
DEAR1 3’UTR sequence and increasing concentration of miR-10b mimic exhibited significant
inhibition of luciferase activity compared to cells transfected with a negative control mimic. B)
HEK293Ts co-transfected with pMIR-REPORT vector and miR-196b mimic also demonstrated
significant reduction of luciferase activity compared to respective controls. Results indicate that
miR-10b and miR-196b are capable of binding to and inhibiting luciferase mRNA to reduce
protein expression and activity.
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Figure 5.4A&B). To test if overexpression of miR-10b or miR-196b in cell lines that express
DEAR1 will affect protein expression, miR-10b and miR-196b mimics were transfected into CCH1 and MCF10A cell lines. Results indicate that both miRNAs reduce DEAR1 protein expression
in both cell lines at various time points (Figure 5.5). This data demonstrates that overexpression
of either miR-10b or miR-196b inhibits luciferase activity, results in inhibition of DEAR1 protein
expression, and thus are potential candidates for regulating DEAR1 expression.
To show that miRNA binding and subsequent translational repression is dependent on
the seed region identified in the DEAR1 3’UTR, a mutant luciferase reporter construct was
generated that harbored a 4-base mutation within the putative miR-10b seed region. Luciferase
assays were performed in HEK293T cells using the standard, putative, and mutant pMIRREPORT constructs. In two separate trials, cells co-transfected with mutant pMIR-REPORT
vector and miR-10b mimic resulted in the rescue of luciferase activity, which was not significantly
different compared to the negative control (Figure 5.6). This demonstrates that inhibition of
luciferase activity is dependent on miR-10b and its ability to bind to the seed region within the
DEAR1 3’UTR and provides further evidence that miR-10b is a candidate regulator of DEAR1
expression.

4.3

Discussion
MiRNAs are short non-coding RNA strands that were first discovered and characterized

in worms in the early 1990s. MiRNA sequences and functions are conserved across multiple
species and there are currently over 2000 known miRNAs in the human genome [160]. The role
that miRNAs play in regulating gene expression has profound and complex effects on major
pathways governing development, cell cycle, and carcinogenesis [161].
Studies of differential miRNA expression in breast cancer revealed a panel of deregulated miRNAs that can be utilized to predict subtypes and clinical outcomes.
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Figure 5.4: Expression of miRNA mimics significantly reduces luciferase activity in
HEK293T cells containing the entire DEAR1 3’UTR sequence containing miRNA binding
sites. A) HEK293Ts co-transfected with 25ng pMIR-REPORT luciferase vector containing
DEAR1 3’UTR sequence and increasing concentration of miR-10b mimic demonstrated
significant repression of luciferase activity compared to cells transfected with a negative control
mimic. B) Similar statistically significant results were obtained with HEK293T cells co-transfected
with pMIR-REPORT and increasing concentration of miR-196b mimic. This indicates that both
miRNAs have affinity to the 3’ UTR of DEAR1 to cause downregulation of luciferase expression.
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Figure 5.5: Transient transfection of miRNA mimics into cell lines that express DEAR1
protein result in reduction of DEAR1 expression. A) CCH-1 DCIS cell line transfected with
200nM miR-10b and miR-196b mimics demonstrated reduction of DEAR1 protein expression 48
hours post-transfection. MiR-10b resulted in 30% reduction while miR-196b resulted in 60%
reduction, as calculated using ImageJ software. B) MCF10A cell line transfected with 200nM
miR-10b mimic also demonstrated 40% reduction of DEAR1 protein expression 48 hours posttransfection whereas transfection with 200nM miR-196b mimic resulted in 40% reduction of
DEAR1 protein 72 hours post-transfection. These results show that ectopic expression of miR10b and miR-196b can inhibit DEAR1 protein expression, making them potential miRNA
regulators of DEAR1.
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Figure 5.6: Mutations in the putative miR-10b binding site in DEAR1 3’ UTR results in
rescued luciferase activity. Two-step PCR mutagenesis was performed using the pMIRREPORT putative vector to generate a 4-base alteration within the predicted miR-10b seed
region. This mutation eliminated repression of luciferase translation and activity. This result
indicates that miR-10b binds to this particular region in the DEAR1 3’UTR to repress translation
and provides evidence that miR-10b can regulate DEAR1 expression.
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Overexpression of miR-155, miR-21, and miR-10b oncomirs is often observed in breast
carcinomas. Several groups have demonstrated downregulation of miR-200 family, miR-205, and
miR-34a that affect EMT-regulators such as ZEB1/2 and SNAI1 [146, 147, 151, 152, 154, 160,
161]. A review by Kurozumi and colleagues summarizes a list of miRNAs associated with breast
carcinogenesis and miRNA expressions that correlate with breast cancer subtypes. For example,
luminal A subtypes often present overexpression of miR-10a, let-7c, let-7f, and miR-191 miR15b and downregulation of miR-206, miR-15b, and miR-107 while basal-like tumors present
overexpression of miR-155, miR17-92, and miR-93 and downregulation of miR-29 and miR-190b
[161]. These studies demonstrate an interesting case in favor of utilizing miRNA expression to
predict patient prognosis and options for personalized therapy.
Mechanisms behind DEAR1 regulation remain elusive. Since miRNAs are often
deregulated in breast carcinomas and DEAR1 is downregulated in DCIS and IDC, we sought to
identify candidate miRNAs that might regulate DEAR1 expression post-transcriptionally. Online
prediction tools generated several candidate miRNAs based on seed region alignment to the
DEAR1 3’ UTR. Among the list, miR-10b and miR-196b were of interest based on published
literature. Both miR-10b and miR-196b were overexpressed in progenitor endothelial cells
associated with tumor vasculature [157]. MiR-10b and miR-196b are overexpressed in most
cancer cell lines that lack DEAR1 expression compared to normal human mammary epithelial
cell lines that express DEAR1 protein. To test each miRNA’s ability to inhibit gene expression,
HEK293T cells were co-transfected with miRNA mimics and a luciferase reporter containing the
DEAR1 3’ UTR. Results consistently demonstrate that ectopic expression of either miR-10b or
miR-196b led to significant repression of luciferase activity compared to cells transfected with a
negative control miRNA. Furthermore, transient transfection of either miRNAs in CCH-1 and
MCF10A cell lines, which express DEAR1 protein, resulted in reduction of DEAR1 expression.
The gene encoding miR-10b on chromosome 2 is frequently amplified in multiple cancer
types, including ovarian, head and neck, pancreatic, prostate, cervical, and breast carcinomas
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[1]. Li Ma and colleagues identified miR-10b as an important regulator of breast cancer
metastasis both in vitro and in vivo. Interestingly, miR-10b is downregulated in early stage breast
carcinomas compared to normal mammary tissue but is overexpressed in some metastatic
lesions and cell lines [149]. MiR-10b is also upregulated in other metastatic and invasive tissues
including pancreatic and hepatocellular carcinomas, glioblastomas, and neurofibromas [148].
Studies have demonstrated that miR-10b overexpression through TGF-β signaling or TWIST
upregulation occurs in late stages of carcinogenesis. Although inhibition of miR-10b with
antagomirs did not result in significant changes in primary tumor formation, it led to a significant
reduction in lung metastases in mice. Expression of miR-10b also associated with increased
stage, lymph node involvement, and higher Ki-67 staining [162]. Since loss of DEAR1 protein
expression associates with shorter time to metastasis and with the TNBC subtype, which is at
higher risk of aggressive behavior and invasion, miR-10b seems to be a logical negative regulator
of DEAR1.
MiR-196b has not been as well studied as miR-10b on its role in breast cancer, however
it has been shown to be overexpressed in hematopoietic cancers and associates with poor OS
in patients with AML [163] and loss of DEAR1 correlates with poor OS and shorter survival in the
same cancer type [105, 106]. Furthermore, overexpression of miR-196b is frequent in colorectal
carcinomas and associates with poor prognosis. Additionally, upregulation of miR-196b in
colorectal carcinoma cells resulted in increased cancer stem cell properties by activating STAT3
signaling through targeting negative regulators of the JAK/STAT pathway, SOCS1 and SOCS3
[164]. This correlation between miR-196b and stemness is of interest given that we have
evidence that DEAR1 also plays a role in mediating stemness in vitro in mammary epithelial cells.
Results herein indicate that miR-10b and miR-196b can target DEAR1 3’ UTR to inhibit
protein expression in multiple cell lines. Although more experiments are required to determine if
DEAR1 is a bonafide target of miR-10b and/or miR-196b, these findings provide a foundation by
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which to continue our investigations into the regulatory mechanisms governing DEAR1
expression.
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CHAPTER 6: Materials and methods
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Cell culture
76N-E6 human mammary epithelial cells were grown in D-medium which consists of 500mL
Minimum Essential Medium Alpha (Corning, MT10022CV), 500mL Ham’s F12K medium
(Corning, MT10025CV),1% FBS (Gibco, 10437028), 2mM L-glutamine (Gibco, 25030081),
10mM HEPES (Gibco, 15630080), 10mg L-ascorbic acid (Sigma, A4403-100MG), 35mg bovine
pituitary extract (Life Technologies, 13028), 12.5ng/mL epidermal growth factor (Sigma, E9644),
1ng/mL β-estradiol (Sigma, E2257), 0.0006% ethanolamine (Sigma, E0135), 1ug/mL
hydrocortisone (Sigma, H0396), 1ug/mL insulin (Sigma, I-1882), 2.5ng/mL Na selenite (Sigma,
S9133), 10mg O-phosphoethanolamine (Sigma, P0503-10MG), 10mg apo-transferin (Sigma,
T5391-10MG), and 1ng/mL triiodothyronine (III) (Sigma, T6397). DEAR1-KD and DEAR1SMAD3 double KD clones were generated previously in the lab by Dr. Nanyue Chen [102]. HEK
293T cells purchased from the MD Anderson characterized cell line core (CCLC) were grown in
DMEM (Corning, MT10017CV) and 5% FBS (Sigma, F8192). MCF10A cells were grown in
DMEM/F12 50/50 (Corning, MT10090CV) supplemented with 5% horse serum (Gibco,
16050114), 10ug EGF, 0.25mg hydrocortisone, 5mg insulin, and 50ug cholera toxin
(CalBioChem, 227036). DCIS.COM cells were propagated in DMEM/F12 medium supplemented
with 5ug/mL horse serum, 10ug/mL insulin, and 0.5ug/mL hydrocortisone. Cells were trypsinized
with 1X TrypLE Express (Gibco, 12605028) for dissociation and passaging.
Western blot analysis
To obtain whole cell lysates, cells were grown in 2D culture as described above, harvested using
1X SDS sample buffer with 50mM DTT, and sonicated before protein measurements were
recorded. Proteins were loaded into a 4-12% SDS-PAGE gradient gel (ThermoFisher Scientific,
NW04120BOX), run on the Bolt Mini Gel Tank, and transferred onto a nitrocellulose membrane
(BioRad, 1620094). DEAR1 antibody was produced by Bethyl Laboratories (Montgomery, TX,
United States). SNAI2/SLUG (C19G7, #9585)) and SMAD3 (C67H9, #9523) antibodies were
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purchased from Cell Signaling (Danvers, MA, United States). Westerns were normalized using
β-actin (A5441) purchased from Sigma (Saint Louis, MO, United States).
Plasmids
The pcDNA-DEAR1 and pCMV-HA-DEAR1 constructs were generated previously in the lab
[100]. The pCMV-HA-DEAR1-C11A RING mutant vector was generated by Dr. Balasenthil using
the Stratagene QuikChange Site-Directed Mutagenesis kit (210518). The SNAI2 cDNA was
amplified from the pEGFP-C2-SLUG vector from Dr. Togo Ikuta at the Research Institute for
Clinical Oncology using PCR and ligated into a pcDNA-6Myc vector digested with EcoRI and
XhoI. pMT123-8x-HA-Ubiquitin was a generous gift from Dr. Dirk Bohmann from Rochester
Medical Center. 3x-Flag-Ubiquitin was provided by Dr. Garrison Fathman at Stanford University.
pGL3-SNAI2 promoter luciferase plasmid was provided by Dr. Togo Ikuta. For miRNA studies,
pMIR-REPORT luciferase plasmid was purchased from Addgene. Luciferase readings were
normalized to β-galactosidase (Promega).
Primers
To amplify SNAI2 from the pEGFP-C2 backbone via PCR, forward and reverse primers were
designed to include EcoRI and XhoI restriction enzyme cut sites, respectively, for ligation into the
pcDNA-6Myc backbone (FW primer, 5’-TAACGAGAATTCATGCCGCGCTCCTTC-3’; RV primer,
5’-TCGTTACTCGAGTCAGTGTGCTACACAGCA-3’). To clone the DEAR1 3’UTR region,
forward and reverse primers were designed to include SpeI and HindIII restriction enzyme cut
sites, respectively, for ligation into the pMIR-REPORT luciferase plasmid (FW primer, 5’TAGTCAACTAGTAACACCGTCCGCATCTAGTC-3’;

RV

primer,

5’-

GCCGGACAAGCTTTGATCATAACTCATAAAATGGGCAA-3’. Short DNA oligos containing the
specific DEAR1 3’UTR sequences where the miRNAs of interest were predicted to bind (termed
“putative”) as well as the exact sequences where the miRNAs were predicted to bind (termed
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“standard”) were ligated into pMIR-REPORT. To generate mutations in miRNA binding region in
the 3’UTR, primers were designed to include a four-base changes.
Co-immunoprecipitation and ubiquitination assays
For co-immunoprecipitation (Co-IP) assays, HEK293T cells were transfected with Myc-SNAI2
and/or HA-DEAR1 plasmids in a 6cm plate, treated with MG-132 proteosome inhibitor
(Calbiochem, 133407-82-6) for 2 hours, and harvested at 24 hours post transfection. Mirus
TransIT-LT1 transfection reagent (Mirus, MIR 2300) was used at a ratio of 1:3 (DNA:Mirus). Cells
were lysed with M-PER lysis buffer (ThermoFisher Scientific, 78501) and incubated with pulldown antibody overnight at 4oC. The following morning, lysates were incubated with protein A/G
agarose beads (Santa Cruz, sc-2003) for 2 hours at 4oC followed by three 5-minute washes with
RIPA lysis buffer. Proteins were eluted from beads in 30uL of 2X SDS sample buffer for western
blot analysis. Anti-HA (H6908) or anti-Myc (M4439) from Sigma were used for pull-down and
anti-HA (H3663) from Sigma or anti-Myc (#562) from MBL International Corporation were used
for immunoblotting. Ubiquitination assays were set up in a similar manner using HEK293T
transfected with Myc-SNAI2, 8x-HA-Ub, and/or DEAR1 plasmids in a 10cm plate. When using
the HA-DEAR1-C11A RING mutant plasmid, 3x-Flag-Ub was substituted for 8x-HA-Ub. Cells
were harvested at 48 hours post transfection, lysed with 1X SDS, and denatured at 95oC for 10
minutes. Cell lysates were diluted with NP-40 buffer prior to western blot analysis.
Real time quantitative PCR
Cells were treated with 4ng/mL TGF-β1 (EMD Millipore, 616450-1UG) for 3 and 40 hours; cells
were harvested for RNA extraction using High Pure RNA Isolation Kit (Roche, 11828665001),
followed by a quality check using MD Anderson’s Microarray Core. RNA was reverse transcribed
using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 4368814). Real
time quantitative PCR was performed using TaqMan® Universal Master Mix II, no UNG (Applied
Biosystems, 4440047) and TaqMan® probes for TRIM62 (Hs00217089_m1), SNAI2
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(Hs00950344_m1),

ZEB1

(Hs00232783_m1),

ZEB2

(Hs00207691_m1),

and

GAPDH

(Hs02786624_g1) in triplicate and in MicroAmp optical 384-well plates (Applied Biosystems,
4309849). ΔΔCt values were normalized to GAPDH. For miRNA expression, RNA was collected
using the miRNeasy Mini Kit (Qiagen, 217004) and reverse transcribed using TaqMan™
MicroRNA Reverse Transcription Kit (Applied Biosystems, 4366596). ΔΔCt values were
normalized to U6 snRNP.
Luciferase Assay
293T cells were plated at a density of 100,000 cells in a 12-well flat bottom cell culture plate
(Corning, 3513) and allowed to adhere overnight. Culture medium was replaced prior to
transfection. Cells were transfected using Mirus TransIT-LT1 reagent with 50ng pGL3-SNAI2
luciferase vector, 10ng β-galactosidase, and either pcDNA empty vector or pcDNA-DEAR1 (200,
300, and 400ng). Cells were lysed with 1X Passive Lysis Buffer (Promega, E1941). The
Luciferase Assay System (Promega, E1501) was used to measure luciferase activity. βgalactosidase activity, for normalization, was measured using the Galacto-Light Plus Reporter
Gene Assay System (Applied Biosystems, T1007). Activities were measured using a 20/20n
Luminometer (Turner Biosystems, 998-2036). For miRNA studies, 293T cells were transfected
using DharmaFECT transfection reagent (Dharmacon, T-2001-01) with 25ng of pMIR-REPORT
(control, DEAR1 3’UTR, putative, or standard), 10ng β-galactosidase, and 100 – 250ng miRNA
mimics or 250ng control mimic (Invitrogen, 4464066).
Mammosphere assay
The mammosphere protocol was given to us by Dr. Sendurai Mani’s Lab and modified from Dontu
et al. [57, 58]. Human mammary epithelial cells were grown in 2D culture in respective normal
growing conditions. Cells pre-treated with TGF-β were treated with 4ng/mL TGF-β1 for 48 hours
prior to seeding cells in mammosphere growing conditions. Mammosphere medium was made
using Mammary Epithelial Growth Medium (LONZA, CC-3051), 1% methylcellulose (400cp,
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Sigma, M0430-100G), 20ng/mL bFGF (Corning, 47743‐574), 10ng/mL EGF (Sigma, E9644.2MG), and 4ug/mL heparin (Sigma, H3149-50KU), and filtered through a 0.45uM filter (VWR,
28145-481) before use. Cells grown and treated in 2D culture were trypsinized with 1X TrypLE
Express and counted using a hemocytometer. Cells were seeded at 1x103 cells per well in flat
bottom ultra-low attachement 96-well plates (Corning, 3474). Mammospheres were replenished
with fresh medium every two days; mammopsheres were counted and imaged using a Zeiss light
microscope at 10X magnification on Day 14. Secondary and tertiary mammospheres were
generated by harvesting primary mammospheres, chemical dissociation with 1X TrypLE
Express, and mechanical dissociation with a pipette to achieve single cell suspension. Cells were
re-counted and seeded at a density of 500 cells per well.
Statistical analysis
Graphs and statistical analyses were performed using GraphPad Prism 6. Statistical analysis
was performed using one-way ANOVA multiple comparison or student’s t-test. Statistical
significance refers to p-values less than or equal to 0.05 (*=0.01-0.05, **<0.01, ***<0.001,
****<0.0001).
Immunofluorescence
Whole mammospheres were collected and resuspended in 100uL of 1X PBS (Corning,
21040CV) for cytospin using Shandon Cytospin 4 (Thermo Scientific, 1000rpm, 8min) onto
Shandon Cytospin slides (Thermo Scientific, 5991056) using filter cards (Thermo Scientific,
5991022), then fixed with Safetex cytology spray fixative (Andwin Scientific, PK6000). Slides
were stained using standard immunofluorescence staining protocol using 0.3% Triton X-100 in
PBS for permeabilization and blocked with anti-Goat serum for one hour at 4C. Anti-CK8/18
(rabbit, Abcam, cat#: ab53280-uL, 1:100), anti-CK5 (mouse, Pierce, cat#: MA5-17057, 1:100),
and ALDH1A1 (rabbit, Abcam, cat#: ab52492‐10ul, 1:100) were used to detect co-expression of
luminal and basal cytokeratins and a marker of stem/progenitor cells. Secondary antibodies goat
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anti-mouse (Alexa 488) and goat anti-rabbit (Alexa 555) were used. Nuclei were stained with
DAPI (Sigma, 236276). Slides were treated with ProLong Gold anti-fade fluorescent mounting
agent (ThermoFisher Scientific, P10144). Fluorescent images were taken using OLYMPUS
cellSens Software.
Tumor tissue microarray
In collaboration with Dr. Ignacio Wistuba, Dr. Aysegul Sahin, and Dr. Fei Yang from the
Department of Translational Molecular Pathology at MDACC, DEAR1 staining was analyzed on
a tissue microarray of 180 breast cancer samples, 103 of which are triple negative breast
cancers, using Aperio Technologies. We obtained archival, formalin-fixed and paraffinembedded (FFPE) material from surgically resected breast cancer specimens from the Breast
Tumor Bank at M. D. Anderson Cancer Center from 2001 to 2013 (Houston, TX). Tumor tissue
specimens obtained from 180 breast cancers were histologically examined, classified using the
World Health Organization (WHO) classification of Breast Tumors and selected for TMA
construction. After histologic examination, tumor TMAs were prepared using triplicate 1-mmdiameter cores per tumor. Detailed clinical and pathologic information, including demographic,
pathologic TNM staging, overall survival, and time of recurrence was collected. Dr. Suyu Liu and
Dr. Laura Rubin from the Department of Biostatistics at MDACC performed statistical analyses
to determine if DEAR1 expression correlates with clinical status. Wilcoxon or Kruskal-Wallis rank
sum tests were used to study the association between categorical and continuous variables.
Survival curves were estimated using the Kaplan-Meier method and differences in survival
between groups were assessed using two-sided log-rank tests. Hazard ratios were obtained from
univariate Cox proportional hazards regression models. Overall survival and time to metastasis
were defined as the time between date of surgery and date of death or date of metastasis,
respectively. R version 3.4.2 was used to perform statistical analyses.
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CHAPTER 7: Discussion and future directions
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Discussion
Breast cancer affects hundreds of thousands of women worldwide. In the United States,
breast cancer remains the most commonly diagnosed cancer in women annually [1]. Triple
negative breast cancer is the most aggressive subtype of breast cancer, characterized by
invasive potential, high risk of metastasis, shorter survival time, and overall poor prognosis [6,
10, 11]. Subgroups of the TNBC subtype include basal-like, immunomodulatory, mesenchymal,
mesenchymal stem cell-like, and luminal androgen receptor [165]. Each subgroup is
distinguished by differential gene expression profiles. For example, basal-like tumors associate
with overexpression of cell cycle genes, DNA damage regulators, and BRCA1 mutations
whereas the mesenchymal subgroup is associated with overexpression of EMT regulators [161,
165]. Prognosis of breast cancer when detected early is favorable with a 98.7% 5-year survival
rate. However, once the disease has metastasized, the 5-year survival rate drops to 27% [1]. It
is crucial that we identify and understand molecular pathways that are involved in the invasion
and metastatic process in order better treat breast cancer patients.
One of the earliest events leading up to dissemination of cancer cells from the primary
tumor is initiation of the EMT program and loss of apical-basal polarity that mediates invasive
potential [32, 126, 141, 166]. DEAR1 is a tumor suppressor mapped to Chromosome 1p35.1, a
region within the 1p interval that frequently undergoes loss of heterozygosity in breast cancer [4].
At the molecular level, DEAR1 was demonstrated as a crucial regulator of apical-basal cell
polarity and required for proper acinar formation in vitro [100]. Shortly after, DEAR1 was
discovered as a negative regulator of TGF-β-mediated EMT through binding and
polyubiquitinating the canonical effector protein, SMAD3, leading to repression of transcriptional
activation of EMT regulators [102]. In a cohort of 158 early-onset breast cancer patients under
the age of 49 years, loss of DEAR1 protein expression significantly correlated with PR negative
and TNBC status and associated with strong family history [100]. Presence of DEAR1 protein
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expression was a positive indicator of recurrence-free survival after a 15-year follow-up in this
cohort, further implicating the importance of DEAR1 in breast carcinogenesis.
The concept of cancer stem cells as tumor-initiating cells has been established for nearly
five decades [67]. Within the last ten years, an overwhelming number of studies have connected
initiation of EMT or overexpression of EMT transcription factors, including SNAI1/2, ZEB1, and
FOXC2, to the generation of cancer stem cells [32, 57, 69, 76, 85, 127, 129, 131, 167, 168].
Since it was previously demonstrated in that DEAR1 mediates invasion and migration through
regulation of TGF-β-induced EMT in mammary epithelial cells and that DEAR1 functions as a
tumor suppressor by repressing invasive potential in lung adenocarcinoma and ovarian cancer
cell lines [102, 104, 107], I hypothesized that DEAR1 may also regulate stem cell properties and
that its expression can be utilized to distinguish breast cancer patients who are at risk for
progression or metastasis.
To study DEAR1’s role in modulating the stem cell phenotype, I utilized previously
established stable DEAR1 KD HMECs for mammosphere assays to assess self-renewal and
differentiation properties. While confirming that TGF-β enhances the mammosphere phenotype
in the context of DEAR1 downregulation in HMECs and that this is in part regulated through
SMAD3 signaling, I also demonstrate that loss of DEAR1 expression enhances mammosphere
formation independently of its function in regulating the canonical TGF-β and SMAD3 pathway.
This is an important revelation given that not all cancer cells respond in the same manner to
TGF-β stimulation. Since its discovery in the late 1970s, several published studies demonstrated
the paradoxical influence of TGF-β signaling. While TGF-β is a potent inhibitor of cellular growth
and proliferation through its inhibition of C-MYC and CDK4 expression, induction of cell cycle
inhibitor p15INK14B, and promotion of apoptosis in several cell lines [37-39], others have shown
that TGF-β can also promote cell proliferation in certain cancer cell lines and immortalized cell
lines that harbor inactivated RB and TP53 tumor suppressors [44, 46, 120]. I observed this
difference in response to TGF-β in the MCF10DCIS.COM cells grown in mammosphere
conditions. All DCIS.COM cells treated with TGF-β and grown in mammosphere medium resulted
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in a significant reduction of mammospheres compared to control cells treated with DMSO,
possibly because DCIS is an early stage of breast cancer and the HMECs utilized in
mammosphere assays were immortalized by HPV-E6, thus the growth inhibitory effects of TGFβ does not affect HMECs, which harbor inactivated p53. The mammosphere phenotype was also
different in DEAR1-KD and -KO DCIS cells compared to DEAR1-KD HMECs in that loss of
DEAR1 in DCIS cells resulted in significantly larger mammospheres instead of a difference in
mammosphere quantity. Despite the phenotypic difference between DCIS and HMEC
mammospheres, larger mammospheres is indicative of a proliferative progenitor cell population
[58, 112]. The data suggesting that DEAR1 regulates progenitor cell properties in DCIS
corresponds with the data that loss of DEAR1 does not confer the ability to self-renew in HMECs
although I identified bipotent and ALDH1-positive cells within HMEC mammospheres.
Furthermore, loss of DEAR1 in HMECs resulted in a larger population of EpCAM-/CD49f+ basal
progenitor cells and reduction of CD24 luminal marker expression, indicating that DEAR1 might
regulate differentiation and progenitor cell properties. The data presented demonstrates that
DEAR1, a regulator of EMT, can affect progenitor cell properties without initiation of an EMT
program through TGF-β signaling (Figure 7.1). Perhaps cells require additional alterations, such
as upregulation of oncogenes, in addition to loss of DEAR1 to generate stem-like cells.
Using qRT-PCR and western blot analysis, I identified SNAI2 as a candidate target of
DEAR1 regulation. SNAI2 mRNA and protein levels were elevated in DEAR1-KD HMECs at
basal level in the absence of TGF-β treatment. I demonstrate that ectopic expression of DEAR1
inhibits expression of a luciferase construct containing the SNAI2 promoter, providing further
evidence that DEAR1 negatively regulates SNAI2 expression. SNAI2 basal mRNA level was also
unaffected by loss of SMAD3 expression in DEAR1-KD HMECs, indicating that SNAI2
expression can be modulated by other mechanisms independent from the canonical TGF-β
pathway. Several studies have demonstrated that overexpression of EMT transcription factors
regulate stem and/or progenitor cell properties independent of TGF-β signaling, specifically
factors that are expressed and tightly regulated during embryogenesis including SNAI proteins,
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Figure 7.1: DEAR1 is a regulator of cell polarity, EMT, and stem/progenitor cell properties.
DEAR1 functions as a critical regulator of acinar morphogenesis through regulation of apicalbasal cell polarity and inhibitor of TGF-β-mediated EMT in HMECs. Initiation of EMT was shown
to induce acquisition of stem/progenitor cell properties and generate CSCs that are resistant to
standard chemotherapies and contribute to tumor recurrence. Our data reveals that DEAR1 can
regulate stem/progenitor cell properties in HMECs partly through the TGF-β-SMAD3 signaling
axis and independently through regulation of master EMT regulator and stemness factor, SNAI2.
Furthermore, we identify potential miRNA regulators of DEAR1 protein expression: miR-10b and
miR-196b.

115

which are overexpressed during gastrulation, in neural crest cells, and in undifferentiated
mesenchymal cells [27, 72, 134]. SNAI2 expression is also associated with poorly differentiated,
metastatic, basal-like and BRCA1 mutant tumors [72, 88]. Studies suggest that SNAI2 is an
important regulator of a stem-like, undifferentiated state in cooperation with other transcription
factors such as SOX9 [27, 87], and inhibits luminal differentiation through repression of luminalspecific markers such as CD24 and MUC1 [72]. As previously mentioned, Liu et al. observed
that overexpression of DEAR1 in human ovarian cancer cell lines resulted in repression of SNAI2
expression mediated through c-Jun [107], providing a mechanism by which DEAR1 may regulate
SNAI2 at the transcriptional level to inhibit stem cell properties. Alternatively, DEAR1 may
regulate SNAI2 indirectly through stabilization of ERα, which inhibits SNAI2 transcription through
recruitment of HDAC1 [136]. Co-IP and ubiquitin assays revealed that in addition to affecting
SNAI2 transcription, DEAR1 also binds to and polyubiquitinates SNAI2. Preliminary data
suggests that this interaction might not be directly through DEAR1’s RING domain, although it is
quite clear that there exists an interaction and that presence of DEAR1 stimulates SNAI2
ubiquitination. Known post-transcriptional regulators of SNAI2 include p53/MDM2, Wnt/GSK3β,
β-Trcp1, and BRCA1, although the precise mechanism of this interaction remains unclear [52,
88, 137]. Currently, experiments are underway to determine if the mammosphere phenotype in
DEAR1-KD HMECs is regulated through SNAI2 by generating DEAR1-SNAI2 double KD clones.
Preliminary data using pooled cells demonstrated a reduction of primary mammospheres
compared to DEAR1-KD alone, however not at a significant level.
Another piece of evidence that supports the hypothesis that DEAR1 negatively regulates
SNAI2 is the inverse relationship between DEAR1 and SNAI2 mRNA expression in breast cancer
samples and that both loss of expression of DEAR1 and overexpression of SNAI2 are
significantly associated with the TNBC subtype. Furthermore, according to patient data collected
from the METABRIC cohort of 2,509 invasive breast carcinoma patients, DEAR1 undergoes loss
of heterozygosity and/or mRNA downregulation in 17% of patients and significantly correlated
with poor overall survival. SNAI2 is amplified and/or overexpressed in 12% of patients and has
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a significant tendency to co-occur with DEAR1 alterations. Although alterations in SNAI2 alone
do not confer a significant correlation with poor overall survival, SNAI2 amplification and/or
overexpression in addition to DEAR1 LOH and/or downregulation correlated with poor survival
(130 months in the unaltered cohort vs 168 months in the altered cohort) at greater significance
when compared to DEAR1 alterations alone, indicating that expression of both DEAR1 and
SNAI2 can be reliable markers of prognosis.
Another impactful observation was that loss of DEAR1 protein expression occurred
frequently in women who developed TNBC before the age of 50. Furthermore, patients with low
DEAR1 protein expression experienced a significantly shorter time to metastasis compared to
patients with high DEAR1 expression. I find this data of significant value because TNBC has a
tendency to affect women younger than 50 years of age and this subtype, given its aggressive
behavior, is at higher risk of metastasis compared to other breast cancer subtypes. This
corresponds with our previous data in which loss of DEAR1 associated with the TNBC subtype
and strong family history in a cohort of young women diagnosed with IDC. This data indicates
that DEAR1 may serve as a predictor of early onset TNBC and an indicator of metastasis risk.

Future directions
The data presented herein demonstrate that DEAR1 plays a role in the acquisition of
progenitor cell properties and that its expression in breast cancer patients can be potentially
useful in determining risk and prognosis. Further work is required to better comprehend the
precise mechanism by which DEAR1 governs progenitor cell fate in mammary epithelial cells.
Additional in vitro assays, such as the colony forming cell (CFC) assay to visualize the
ability of DEAR1-KD clones to generate luminal and basal-mixed colonies, thus confirming that
loss of DEAR1 promotes the generation of bipotent progenitor cells [169], or assaying for coexpression of other markers indicating bipotency, such as surface markers CD10, MUC1, and α6-integrin [58, 73, 169] and stem/progenitor markers such as Oct4 and Nanog by western blot
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analysis or immunofluorescence, can be performed to confirm that loss of DEAR1 confers
progenitor cell properties. Another gold-standard assay to study progenitor cell properties is to
grow control and DEAR1-KD clones in differentiation medium to determine the potential of each
clone to generate lineage-specific cell types, such as ductal or alveolar cells [114]. Other
functional assays are required to demonstrate that DEAR1 is an important regulator of progenitor
cell properties. One such assay includes a rescue experiment in which ectopic expression of an
RNAi-resistant DEAR1 plasmid is performed in DEAR1-KD cells to test mammosphere formation
efficiencies.
Since I observed a phenotypic difference in mammosphere formation between HMECs
and DCIS.COM cells, it would be of interest to determine if DEAR1 regulates progenitor cell
properties in DCIS cells through the same mechanism by which it governs progenitor cell
properties in HMECs. One way to do so on a large-scale analysis would be to perform a reverse
phase protein array (RPPA) to compare the differential protein expressions between control
vector and DEAR1-KD clones from both HMECs and DCIS.COM clones to identify potential
pathways that mediate the mammosphere phenotype in DCIS cells. Although data suggests that
DEAR1 does not confer stem cell self-renewal capabilities, a labeling assay using PKH26
fluorescent dye can be used to study if loss of DEAR1 affects asymmetric division, a property of
stem cells, in HMECs and DCIS. Cells are labeled with PKH26, plated in mammosphere growth
conditions, and monitored over time to visualize dye distribution upon division. Asymmetric
divisions are determined by fluorescence intensity: if one first-generation daughter cell remains
quiescent and the other cell continues to divide, their progeny will display various PKH intensities
within the mammosphere; alternatively in symmetric divisions, both cells divide at the same rate
and all progeny will have the same relative PKH intensity. This assay was performed in a study
by Cicalese and colleagues using an ERBB2 transgenic model to demonstrate that p53 was
necessary to mediate asymmetric division; absence or mutation of p53 resulted in increased
symmetric division, generating a larger population of stem-like cells [170]. We have unpublished
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data by Dr. Balasenthil that shows DEAR1 plays a role in binding to and stabilizing p53. Since
the DCIS.COM cell line expresses p53 and DEAR1, it would be of interest to evaluate stability of
p53 in the context of DEAR1 loss of expression and determine if this affects symmetric divisions
in DCIS cells.
We established that DEAR1 regulates progenitor cell properties independent of TGF-βSMAD3 signaling potentially through regulating SNAI2 at the transcriptional and posttranslational level. At the transcriptional level, it would be of interest to determine if DEAR1
modulates SNAI2 expression through interaction with transcription factors or transcriptional
repressor complexes that are known to regulate SNAI2 gene expression, such as c-Jun, Mi2/NuRD, or NCOR1. Although we have not demonstrated that DEAR1 localizes to the nucleus in
HMECs, there are known TRIM proteins that mediate gene transcription including TRIM24
(TIF1α), TRIM19 (PML), and TRIM27 (RFP). TRIM24 was demonstrated to bind to chromatin
and histone modifiers, including NCOR1, as well as mediate gene-specific transcriptional control
through interaction with the AF-2 domain of nuclear receptors such as ER and RAR [171, 172].
TRIM19 was also demonstrated to activate the nuclear receptor PR, interact with histone
acetyltransferase CBP to activate transcription of target genes, as well as negatively regulate
gene transcription through association with histone deacetylases through formation of PMLnuclear bodies. The function of TRIM27 is less understood but it was suggested that TRIM27
associates with PML-nuclear bodies and also negatively regulates gene transcription through
interaction with RB and histone deacetylase complexes [171, 173]. At the post-translational level,
we observed an interaction between DEAR1 and SNAI2 that resulted in SNAI2 polyubiquitination.
Data suggests that this interaction was not affected by the C11A point mutation in DEAR1’s RING
domain, but more experiments can be done to determine which domain is required for SNAI2
binding. As mentioned previously, there are several known regulators of SNAI2 and it would be
interesting to test if DEAR1 complexes with any of these mediators of SNAI2 activity. We have
unpublished data that suggests DEAR1 interacts with p53, which has been shown to directly bind
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to and promote SNAI2 ubiquitination through recruitment of MDM2. Functional assays utilizing
mammospheres are required to confirm our theory that DEAR1 is a regulator of progenitor cell
properties through SNAI2 activity. Alternatively, SNAI2 expression may not be the only factor in
mediating this phenotype in HMECs. Preliminary data from RPPA using HMEC mammospheres
identified potential candidate proteins and pathways that are deregulated in DEAR1-KD HMECs,
including Annexin A1 (AnxA1), and Collagen Type VI Alpha 1 Chain (COL6A1). ANXA1 and
COL6A1 both have roles in regulating EMT and are overexpressed in triple negative/basal-like
breast cancer and cell lines, respectively [139, 174, 175], which correlates well with the discovery
that DEAR1 expression is reduced in this subtype of breast cancer. TAZ, a well-known regulator
of cell proliferation through the Hippo signaling pathway, has been shown to confer stem cell
properties in breast cancer cell lines (e.g. mammosphere formation, self-renewal, and
CD44high/CD24low signature [82, 83, 125, 168, 176]) and was slightly abundant in DEAR1-KD
mammospheres compared to controls.
I would also like to further investigate if DEAR1 and SNAI2 expression levels are good
predictors of overall survival or risk of early-onset breast cancer or metastasis. To do so, more
patient samples are required to test these associations. In particular, we would like to evaluate if
DEAR1 and SNAI2 protein expressions demonstrate the same inverse relationship in DCIS and
IDC cases as was observed at the mRNA level in basal-like cancers and TNBC. Furthermore, I
would like to utilize the same TNBC TMA to stain for SNAI2 protein expression and assess if it
strengthens the association between DEAR1 staining with age of diagnosis and time to
metastasis. Additionally, I would like to include normal controls and DEAR1 expression at time
of diagnosis rather than at time of surgery to better analyze the association between DEAR1 and
clinical outcomes and potentially use this information to predict prognosis.
There are currently ongoing clinical trials to study the efficacy of anti-EMT drugs that
target specific regulators of the EMT process and also show effectiveness against CSCs that are
dependent on EMT activation. Silmitasertib (CX-4945) is a CK2 serine-threonine kinase small
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molecule inhibitor undergoing Phase I/II clinical trials that was demonstrated to inhibit SMADdependent and -independent TGF-β signaling and reduced expression of EMT-related markers
in late stage solid tumors [177]. LY2157299 is a small molecule inhibitor of TGF-β undergoing
Phase II/III clinical trials that was shown to be effective in treating TNBCs that have developed
resistance to chemotherapy and hypothesized to target residual CSCs that were unaffected by
conventional chemotherapy agents [177]. Salinomycin is another small molecule inhibitor that
showed efficacy of reducing CSC populations through induction of apoptosis, though the precise
mechanism is still being investigated. Natural compounds such as sulforaphane found in broccoli
and resveratrol found in grapes were shown to be effective against CSCs through inhibition of
the Wnt/β-catenin pathway and metastasis through inhibition of SNAI1/2, respectively [178, 179].
Since I observed a stem/progenitor cell phenotype in cells that have undergone loss of DEAR1
expression in both the absence and presence of TGF-β signaling, using these compounds to test
their efficacies on mammosphere formation will provide insight into how we can potentially use
DEAR1 expression to stratify patients for personalized targeted therapies in addition to standard
chemotherapeutic agents.
Additionally, I would like to expand our investigations regarding transcriptional and posttranscriptional regulation of DEAR1. Several oncogenes and tumor suppressors are upregulated
or downregulated, respectively, in cancers due to deregulation of miRNAs. The most notable
ones involved in EMT and metastasis includes miR-34a, which negatively regulates SNAI1
expression and is downregulated in breast cancer [147]; miR-200 family members, which target
ZEB1 and ZEB2 mRNA and is repressed during invasion and metastasis but re-expressed upon
colonization at secondary sites [53, 129]; miR-10b is involved in mediating metastasis, was
demonstrated to be upregulated in late-stage breast cancers, and associated with the TNBC
subtype [148, 149, 151, 154, 162]; miR-155 expression was shown to be regulated by BRCA1,
is overexpressed in breast cancer, and demonstrated to target genes involved in cancer cell
migration, invasion, survival, and proliferation [180]. Preliminary data suggests that DEAR1
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mRNA could be targeted by miR-10b and miR-196b. Further functional assays can be performed
to confirm that these miRNAs target DEAR1, including additional mutation assays, in vivo
correlational studies, and associative studies using patient samples. Therapeutically, I can test if
treatment with antagomir-miR-10b can increase DEAR1 expression in cancer cell lines and the
effects on CSC properties.
DEAR1 was demonstrated as a tumor suppressor and critical regulator of apical-basal
polarity and EMT initiation. Altogether, results from this study demonstrates a novel role for
DEAR1 in the regulation of stem/progenitor cell properties in HMECs and DCIS cells, through
modulation of SNAI2, a potent regulator of stemness in mammary epithelial cells. I further
identified an inverse correlation between DEAR1 and SNAI2 expression in patient samples,
indicating their prognostic significance, and revealed significant associations between DEAR1
expression with age of diagnosis and time to metastasis in TNBC, the most aggressive and
difficult to treat breast cancer subtypes. With this information, I hope to utilize our understanding
of DEAR1 to stratify patients who are at risk for progression and would benefit from therapies
that target DEAR1-regulated pathways.
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